

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(10) International Publication Number  
**WO 2018/005975 A1**

(43) International Publication Date  
04 January 2018 (04.01.2018)

(51) International Patent Classification:

A61K 48/00 (2006.01) C12N 5/071 (2010.01)  
C12N 15/00 (2006.01) C07H 21/04 (2006.01)  
C12N 5/07 (2010.01)

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,  
KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(21) International Application Number:

PCT/US2017/040303

(22) International Filing Date:

30 June 2017 (30.06.2017)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/357,585 01 July 2016 (01.07.2016) US  
62/436,233 19 December 2016 (19.12.2016) US

(71) Applicant: **RESEARCH DEVELOPMENT FOUNDATION** [US/US]; 402 North Division Street, Carson City, NV 89703 (US).

(72) Inventors: **KRAUSE, Karl-Heinz**; c/o Geneva Medical School, University Of Geneva, Rue Michel Servet 1, 1211 Geneva (CH). **DUBOIS-DAUPHIN, Michel**; c/o Geneva Medical School, University Of Geneva, Rue Michel Servet 1, 1211 Geneva (CH). **TIENG CAULET, Vannary**; c/o Geneva Hospitals, 4, rue Gabrielle-Perret-Gentil, 1205 Geneva (CH).

(74) Agent: **BYRD, Marshall, P.**; Parker Highlander PLLC, 1120 S. Capital of Texas Highway, Building One, Suite 200, Austin, TX 78746 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: ELIMINATION OF PROLIFERATING CELLS FROM STEM CELL-DERIVED GRAFTS

(57) Abstract: Provided herein are methods and compositions for a suicide gene approach comprising an expression vector comprising a cell cycle-dependent promoter driving the expression of a suicide gene. Also provided herein are methods to render proliferative cells sensitive to a prodrug after transplantation but avoids expression of the suicide gene in post-mitotic cells, such as neurons.



WO 2018/005975 A1

## **DESCRIPTION**

### **ELIMINATION OF PROLIFERATING CELLS FROM STEM CELL-DERIVED GRAFTS**

[0001] This application claims the benefit of United States Provisional Patent  
5 Application Nos. 62/357,585, filed July 1, 2016, and 62/436,233, filed December 19, 2016, the  
entirety of which are incorporated herein by reference.

[0002] The sequence listing that is contained in the file named  
“CLFR\_P0403WO\_ST25.txt”, which is 9 KB (as measured in Microsoft Windows) and was  
created on June 29, 2017, is filed herewith by electronic submission and is incorporated by  
10 reference herein.

## **BACKGROUND OF THE INVENTION**

### **1. Field of the Invention**

[0003] The present invention relates generally to the field of stem cell therapy. More  
particularly, it concerns the specific elimination of proliferating cells in stem cell-derived  
15 grafts.

### **2. Description of Related Art**

[0004] Parkinson's disease (PD) is a neurodegenerative disorder characterized by the  
loss of the nigrostriatal pathway. Although the cause of Parkinson's disease is not known, it is  
associated with the progressive degeneration or death of dopaminergic (*i.e.*, tyrosine  
20 hydroxylase (TH) positive) neurons in the substantia nigra region of the basal ganglia, which  
induces progressive deterioration of motor function control. The characteristic symptoms of  
Parkinson's disease appear when up to 70% of TH-positive nigrostriatal neurons have  
degenerated.

[0005] There is currently no satisfactory cure for Parkinson's disease. Symptomatic  
25 treatment of the disease-associated motor impairments involves oral administration of  
dihydroxyphenylalanine (L-DOPA). L-DOPA is transported across the blood-brain barrier and  
converted to dopamine, partly by residual dopaminergic neurons, leading to a substantial  
improvement of motor function. However, after a few years, the degeneration of dopaminergic  
neurons progresses, the effects of L-DOPA are reduced and symptoms reappear.

[0006] Deep brain stimulation (DBS) therapy is the current preferred treatment for Parkinson's disease. DBS is a treatment of Parkinson's disease that aims to change the rates and patterns of activity of brain cells by implanting a brain stimulator (*i.e.*, an electrode) into a target region in the brain known to be associated with movement, such as the subthalamic nucleus, basal ganglia structures, including the globus pallidus internalis, or ventrointermediate nucleus of the thalamus. However, the success of DBS procedures can diminish over time. Therefore, better therapy for Parkinson's disease is necessary.

[0007] A treatment method for Parkinson's disease currently in development involves the transplantation of partially differentiated neuroepithelial cells (*i.e.*, neural progenitor cells) into brain regions lacking sufficient dopaminergic signaling; these cells then differentiate into dopaminergic neurons *in vivo*. The potential of neural progenitor cells to differentiate into dopaminergic neurons was demonstrated both with rodent and human PSC (Kriks *et al.*, 2011; Wernig *et al.*, 2008). Moreover, the potential of PSC-derived neural progenitor cells to reinnervate the striatum in drug-lesioned rodent and primate models of Parkinson's disease was shown (Ganat *et al.*, 2012; Kriks *et al.*, 2011; Wernig *et al.*, 2008).

[0008] However, not all transplanted neural progenitor cells differentiate into the desired neuronal subtypes and instead remain as proliferating cells within the graft, which leads to overgrowth and tumor formation. Even the most advanced protocols available (Ganat *et al.*, 2012) have been unable to overcome the problem of residual proliferating cells forming neuroepithelial tumors during PSC-derived neural progenitor cell-based therapy of CNS diseases. Therefore, there is an unmet need for methods of eliminating residual proliferating cells following stem cell-based therapy.

### **SUMMARY OF THE INVENTION**

[0009] In certain embodiments, the present disclosure concerns isolated and recombinant polynucleotides, such as polynucleotides comprising a cell-cycle dependent promoter operatively linked to a suicide gene. In one embodiment, there is provided an expression vector comprising a cell cycle-dependent promoter operatively linked to a suicide gene coding sequence.

[0010] In some aspects, the cell cycle-dependent promoter is a Ki-67, PCNA, CCNA2, CCNB2, DLGAP5, or TOP2A promoter. In some aspects, the cell cycle-dependent promoter is a hybrid of Ki-67, PCNA, CCNA2, CCNB2, DLGAP5, or TOP2A promoters. In particular aspects, the cell cycle-dependent promoter is a Ki-67 promoter.

[0011] In certain aspects, the suicide gene is a viral thymidine kinase, bacterial cytosine deaminase, nitroreductase, carboxypeptidase G2, purine nucleoside phosphorylase, or caspase 9. In particular aspects, the suicide gene is a herpes simplex virus thymidine kinase (HSV TK) gene. In some aspects, the HSV TK gene is a mutated version of wild-type HSV TK comprising one or more amino acid substitutions, such as HSV1-SR11TK, HSV1-SR26TK, or HSV1-SR39TK.

[0012] In some aspects, the expression vector further comprises a selectable marker. In certain aspects, the selectable marker is an antibiotic resistance gene or a gene encoding a fluorescent protein.

[0013] In certain aspects, the expression vector is further defined as a viral vector. In some aspects, the viral vector is a lentiviral vector, an adenoviral vector, a retroviral vector, a vaccinia viral vector, an adeno-associated viral vector, a herpes viral vector, or a polyoma viral vector. In particular aspects, the viral vector is a lentiviral vector.

[0014] In another embodiment, there is provided a host cell comprising the polynucleotide comprising a cell-cycle dependent promoter operatively linked to a suicide gene. In particular aspects, the host cell is further defined as a precursor cell. In some aspects, the polynucleotide is introduced into the host cell using a viral vector, such as a lentiviral vector, retroviral vector, an adenoviral vector (*e.g.*, an integrating adenovector), a vaccinia viral vector, an adeno-associated viral vector, a herpes viral vector, or a polyoma viral vector. In particular aspects, the viral vector is a lentiviral vector. The vector may be an integrating vector.

In other aspects, the polynucleotide is introduced into the host cell using a non-viral approach, such as injection of naked DNA, nucleic acid delivery enhanced by physical methods (*e.g.*, electroporation or gene gun), or nucleic acid delivery enhanced by chemical methods (*e.g.*, lipids, liposomes nanoparticles, or cell permeating peptides).

5           **[0015]** In some aspects, the host cell is further defined as a neural precursor cell, cardiomyocyte precursor cell, endothelial precursor cell, pancreatic precursor cell, kidney precursor cell, oligodendrocyte precursor cell, hematopoietic precursor cell, myeloid precursor cell, mesenchymal precursor cell, retinal precursor cell, or osteoclast precursor cell. In particular aspects, the host cell is further defined as a neural precursor cell. In some aspects, 10 the cell is derived from a pluripotent stem cell (PSC). In some aspects, the PSC is an induced pluripotent stem cell (iPS cell) or embryonic stem cell (ESC). In particular aspects, the neural precursor cell is further defined as a cell expressing at least one of the markers selected from the group consisting of musashi, nestin, sox2, vimentin, pax6, and sox1. In certain aspects, the neural precursor cell expresses 2, 3, 4, 5, or all 6 of the markers musashi, nestin, sox2, vimentin, 15 pax6, and sox1.

**[0016]** In a further embodiment, there is provided a host cell comprising an expression vector of the embodiments. In some aspects, the host cell is further defined as a neural precursor cell, cardiomyocyte precursor cell, endothelial precursor cell, pancreatic precursor cell, kidney precursor cell, oligodendrocyte precursor cell, hematopoietic precursor cell, 20 myeloid precursor cell, mesenchymal precursor cell, retinal precursor cell, or osteoclast precursor cell. In particular aspects, the host cell is further defined as a neural precursor cell. In some aspects, the cell is derived from a pluripotent stem cell (PSC). In some aspects, the PSC is an induced pluripotent stem cell (iPS cell) or embryonic stem cell (ESC). In particular aspects, the neural precursor cell is further defined as a cell expressing at least one of the 25 markers selected from the group consisting of musashi, nestin, sox2, vimentin, pax6, and sox1. In certain aspects, the neural precursor cell expresses 2, 3, 4, 5, or all 6 of the markers musashi, nestin, sox2, vimentin, pax6, and sox1.

**[0017]** In an even further embodiment, there is provided a pharmaceutical composition comprising the host cell of the embodiments and, optionally, a pharmaceutically acceptable 30 carrier.

[0018] In another embodiment, there is provided a method of producing host cells (*e.g.*, precursor cells) of the embodiments comprising obtaining a starting population of PSCs; differentiating the PSCs into precursor cells; and isolating and culturing the precursor cells, wherein either the PSCs or the precursor cells are transfected or transduced with a polynucleotide comprising a cell-cycle dependent promoter operatively linked to a suicide gene (*e.g.*, in an expression vector of the embodiments) and selected for the presence of said polynucleotide (*e.g.*, the expression vector), such that the cultured precursor cells comprise the cell cycle-dependent promoter operatively linked to the suicide gene coding sequence.

[0019] In some aspects, the precursor cells are neural precursor cells, cardiomyocyte precursor cells, endothelial precursor cells, pancreatic precursor cells, kidney precursor cells, oligodendrocyte precursor cells, hematopoietic precursor cells, myeloid precursor cells, mesenchymal precursor cells, retinal precursor cells, or osteoclast precursor cells. In certain aspects, the precursor cells are neural precursor cells.

[0020] In certain aspects, the pluripotent stem cell population is an embryonic stem cell. In particular aspects, the pluripotent stem cell population is an induced pluripotent stem cell population.

[0021] In some aspects, differentiating cells of the population into neural precursor cells comprises contacting the pluripotent stem cell population with fibroblast growth factor or epidermal growth factor.

[0022] In certain aspects, the method further comprises contacting the pluripotent stem cell population with N2 and B27. In some aspects, isolating comprises sorting the cells of the population to isolate precursor cells, such as neural progenitor cells.

[0023] In some aspects, cells are selected for the presence of said expression vector by a method comprising contacting the transfected or transduced cells with an antibiotic. In certain aspects, cells are selected for the presence of said expression vector by a method comprising sorting the transfected or transduced cells.

[0024] A further embodiment provides a method of cell replacement therapy for replacing cells that are known to be essentially non-dividing cells, the method comprising administering an effective amount of host cells (*e.g.*, precursor cells) of the embodiments, and administering to the subject an amount of a prodrug that is activated by the suicide gene, the

prodrug being administered in an amount effective to eliminate cycling precursor cells. In some aspects, the subject is a mammal. In certain aspects, the mammal is a mouse, rat, non-human primate, or human. In some aspects, the genome of the host cell comprises a genome essentially identical to the genome of the subject and an expression vector of the embodiments.

5 In some aspects, the essentially non-dividing cells to be replaced comprise dopaminergic cells and the precursor cell population comprises dopaminergic neural precursor cells (*e.g.*, defined as expressing tyrosine hydroxylase or dopamine active transporter). In certain aspects, the subject has Parkinson's disease. In particular aspects, the prodrug is ganciclovir and/or acyclovir. In some aspects, the prodrug is administered more than once. In some aspects, the

10 prodrug is administered after a sufficient period of time for the precursor cells to initiate differentiation. In some aspects, the period of time is 3-6 days, such as 3, 4, 5, or 6 days after administering the precursor cells. In other aspects, the period of time is 7-15 days, such as 7, 8, 9, 10, 11, 12, 13, 14, or 15 days after administering the precursor cells. In other aspects, the precursor cells and pro-drug are administered concurrently. In some aspects, the prodrug is

15 administered by injection

[0025] Other objects, features, and advantages of the present invention will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only, since various changes and modifications within

20 the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.

### **BRIEF DESCRIPTION OF THE DRAWINGS**

[0026] The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present invention. The invention may be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein.

[0027] **FIGS. 1A-1C: Elaboration of a pluripotent stem cell line expressing a suicide gene under the control of a cell cycle-dependent promoter.** (A) Thymidine kinase from herpes simplex virus (HSV-TK) was introduced into a lentiviral vector under the control of a Ki67 promoter fragment. The TK used in this study was a fusion protein containing a C-terminally fused zeocin resistance gene. The construct was transduced into the clinical grade human pluripotent stem cell line HS415 (TK-PSC). TK-PSC cells expressing this enzyme were selected by their resistance to zeocin. (B) Cell preparations used in the present study: pluripotent stem cells (TK-PSC, left panel) were differentiated into neurospheres containing dopaminergic neuroprogenitors (TK-NPC, middle panel) and terminated maturation into dopaminergic neurons (TH staining of TK-neurons, right panel). (C) Characterization of TK-PSC cells in undifferentiated state (upper panel) and upon differentiation into neurons (lower panel). Ki67 and HSV-TK were detected by immunostaining and nucleus by DAPI. Both TK-PSC and TK-Neuron showed staining for Ki67 and HSV-TK which overlap in the merged images.

[0028] **FIGS. 2A-2D: Effect of ganciclovir treatment *in vitro*.** (A) Analysis of expression of proliferation markers (Ki67) and pluripotency markers (nanog, oct3/4) at different stages of the differentiation protocol described in FIG. 1B. Protein expression was analyzed by flow cytometry (mean +/- SEM of 4 independent experiments). (B) a-d: Undifferentiated pluripotent TK-PSC cells were exposed to increasing concentrations of ganciclovir (0, 2.5, 5, and 10  $\mu$ M). (B) e-f: comparison of the effect of 40  $\mu$ M ganciclovir on TK-expressing and control PSC. Note that in control PSC, no ganciclovir toxicity is observed even with the highest concentration of ganciclovir (40  $\mu$ M). Upon neuronal differentiation, TK-expressing cells lose their sensitivity to ganciclovir as predicted by the lack of Ki67-driven TK expression in post-mitotic neurons (see FIG. 1C). (C) Dose response to ganciclovir: TK-PSC, control PSC; TK-neurons, and control neurons were exposed to increasing concentrations of ganciclovir. Cell viability was monitored using calcein. The control PSCs had higher expression of Calcein as compared to the TK-PSCs at increasing concentrations of ganciclovir.



(D) Ganciclovir time course: TK and control PSC, 1 week NPC (TK and control), and 2 week NPC (TK and control) were exposed to 40  $\mu$ M ganciclovir and cell toxicity was monitored using calcein. Data from panel C and D are shown as triplicate determinations and are representative of 3 independent experiments. Error bars = +/-SD, n=3.

5           **[0029] FIGS. 3A-3C: Schedule of cell transplantation and ganciclovir treatment.**

Different transplantation and ganciclovir treatment protocols were used. (A) Schematic representation of the differentiation protocol towards DA neurons. Pluripotent stem cells were cultured as neurospheres for 1 week for midbrain orientation phase, followed by a 2 or 3 week-maturation phase. (B) Transplantation of undifferentiated pluripotent stem cells with early or late ganciclovir treatment. *Early treatment*: undifferentiated pluripotent stem cells were transplanted and ganciclovir (or PBS control) was applied by daily intra-peritoneal injection from day 4 to day 19 post-transplantation. *Late treatment*: undifferentiated pluripotent stem cells were transplanted and ganciclovir (or PBS control) was applied by daily intra-peritoneal injection from day 30 to day 45 post-transplantation. (C) Transplantation of 2 or 3 week NPC: NPC containing- neurospheres were dissociated and transplanted into mice striatum. Ganciclovir (or PBS control) treatment was given from day 4 to day 19 post-transplantation. For all protocols, animals were sacrificed 1 month after termination of ganciclovir treatment.

15           **[0030] FIGS. 4A-4B: Early ganciclovir treatment prevents tumor formation after transplantation of HSV-TK-expressing pluripotent cells.** (A) Transplantation of TK-PSC without ganciclovir treatment: teratoma formation was consistently observed after transplantation of TK-PSC into PBS-treated mice *top panel*: cresyl violet coloration; a-d *lower panels*: immunostaining of the graft (HCM staining allows detection of human typical proteins) show a development mainly towards neural tissue with expression of nestin (for immature neural cells), beta III tubulin (for mature neurons). Proliferative cells are stained with Ki67 and PCNA. (B) Transplantation of TK-PSC with early ganciclovir treatment: absence of teratoma formation and cell proliferation in mice transplanted with TK-PSC followed by early ganciclovir treatment (day 4 to 19 following transplantation); a-d *top panel*: cresyl violet coloration; e-f *lower panels*: immunostaining with HCM, Ki67 and PCNA. Mice were sacrificed and immunohistochemistry was performed one month after termination of ganciclovir treatment. Stainings shown in this figure are representative of 3-5 mice per group. Cells stained positive for Ki67 and HCM or PCNA; the staining overlaps in the merged images.

**[0031] FIGS. 5A-5B: Early ganciclovir treatment and impact on Iba1 and Ki67-positive cells.** (A) In the absence of ganciclovir treatment, there were abundant HSV-TK-containing, proliferating (Ki67), human (HCM) tumor cells; the tumors were infiltrated by microglia (Iba1). (B) In ganciclovir-treated mice, a human cell graft (HCM) was barely detectable and virtually no Ki67 and TK expression was observed in the graft region. Some microglia staining by Iba1 was detectable around the scar of the graft. Mice were sacrificed and immunohistochemistry was performed one month after termination of ganciclovir treatment.

**[0032] FIGS. 6A-6B: Late ganciclovir treatment does not prevent tumor formation after transplantation of HSV-TK-expressing pluripotent cells.** Mice were transplanted with TK-PSC and PBS-treatment (A) or ganciclovir-treatment (B) was initiated one month after transplantation. Treatment was maintained for 15 days, followed by 1 month without treatment before sacrifice. Under these conditions, there was no difference between PBS-treated and ganciclovir-treated mice. The grafts have developed towards a tumor with predominantly neural tissue (beta III tubulin staining). Tumor cells expressed Ki67 and TK, but no Oct3/4. The grafts were vascularized, as evidenced by CD31 staining for endothelial cells.

**[0033] FIGS. 7A-7C: Sequencing of HSV-TK in pluripotent stem cell-derived tumors subjected to late ganciclovir treatment.** (A) 2 weeks ganciclovir treatment was initiated 4 weeks after intrastriatal transplantation of pluripotent stem cells and mice were sacrificed 4 weeks after termination of treatment (as described in FIG. 6). DNA was extracted from PFA-fixed, paraffin-embedded tumor samples and amplified using the indicated PCR primers. (B) Direct sequencing of plasmid DNA and amplified sequences from tumor samples did not detect any mutations. (Amplicon 1 – plasmid = SEQ ID NO: 11; “seq” = SEQ ID NO: 12; Amplicon 2 – plasmid = SEQ ID NO: 13; “seq” = SEQ ID NO: 14; Amplicon 3 – plasmid = SEQ ID NO: 15; “seq” = SEQ ID NO: 16; Amplicon 4 – plasmid = SEQ ID NO: 17; “seq” = SEQ ID NO: 18; Amplicon 5 – plasmid = SEQ ID NO: 19; “seq” = SEQ ID NO: 20) (C) Sequencing of HSV-TK subclones from amplicon 3 and 5 (derived from PCR reactions described for panel B). *amplicon 3*: plasmid DNA used for cell transduction, as well as tumor-derived cDNA clones did not contain the splice donor site found in the HSV-TK reference sequence. However cDNA clones 3 and 4 showed coding non-synonymous mutations. (ref = SEQ ID NO: 21; plasmid = SEQ ID NO: 22; clone 1 = SEQ ID NO: 23; clone 2 = SEQ ID NO:

24; clone 3 = SEQ ID NO: 25; clone 4 = SEQ ID NO: 26; ATP-binding site = SEQ ID NO: 27; nucleotide-binding site = SEQ ID NO: 28) *amplicon5*: none of the cDNA clones showed any mutations. (plasmid = SEQ ID NO: 29; clone 1-7 = SEQ ID NO: 30)

**[0034] FIGS. 8A-8D: Graft development after transplantation of neural precursor cells (NPC).** Mice were transplanted with NPC and treated with PBS or ganciclovir on days 7-22 following transplantation. Mice were sacrificed 4 weeks after the termination of ganciclovir treatment and brains were analyzed. There was no tumor formation, but the grafts had developed into a tissue integrated into the mouse brain. No difference was observed between PBS and ganciclovir treatment **(A)** cresyl violet coloration. Transplants were strongly positive for beta 3-tubulin **(B)** upper panel, and weakly positive for TH **(B)** lower panel. Transplanted cells were PCNA-positive, but Ki67 and BrdU negative **(C and insert)**. **(D)** Size of transplants under different experimental conditions in the absence (grey histogram) or presence (black histogram) of ganciclovir. Histograms on the left and middle show transplants after injection of pluripotent stem cells (PSC) treated for 2 weeks with ganciclovir 5 days (early treatment) or 30 days after cell transplantation (late treatment). Histograms on the right show transplants after injection of NPC treated with ganciclovir, 5 days after transplantation. Error bars = mean $\pm$  SEM, n=3 to 5 in each group of mice. \* p=0,0286 in Mann Whitney test.

## **DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS**

[0035] Pluripotent stem cell (PSC)-based cell therapy is an attractive concept, in particular for neurodegenerative diseases. However, transplantation of undifferentiated PSC or rapidly proliferating precursor cells can lead to tumor formation. Thus, to translate promising animal data into a future clinical use, safety mechanisms to eliminate proliferating cells are needed. Thus, in certain embodiments, the present disclosure provides methods and compositions for a suicide gene approach to eliminate proliferating cells. In an exemplary method, an expression vector is provided based on a cell cycle-dependent promoter (*e.g.*, Ki67) driving the expression of a suicide gene (*e.g.*, herpes simplex virus thymidine kinase (HSV-TK)). Thus, this construct provides methods to render proliferative cells sensitive to ganciclovir after transplantation but avoids expression of the antigenic viral HSV-TK protein in post-mitotic neurons.

[0036] The present disclosure shows that host cells comprising the exemplary Ki67-HSV-TK construct killed proliferating PSC and early neural precursor cells (NPC) by exposure to ganciclovir *in vitro*. In addition, *in vivo* transplantation of PSC induced a teratoma which was prevented by early (*e.g.*, 4 days post-transplant) treatment with ganciclovir. Thus, the suicide gene approach of the present disclosure allows killing of proliferating undifferentiated and/or overgrowth of early precursor cells without expression of the suicide gene in mature neurons. This approach has the potential to be useful for other stem cell-based therapies, where the final target is a post-mitotic cell (*e.g.* cardiomyocytes, or pancreatic beta cells).

### **I. Definitions**

[0037] As used herein, “essentially free,” in terms of a specified component, is used herein to mean that none of the specified component has been purposefully formulated into a composition and/or is present only as a contaminant or in trace amounts. The total amount of the specified component resulting from any unintended contamination of a composition is therefore well below 0.05%, preferably below 0.01%. Most preferred is a composition in which no amount of the specified component can be detected with standard analytical methods.

[0038] As used herein the specification, “a” or “an” may mean one or more. As used herein in the claim(s), when used in conjunction with the word “comprising,” the words “a” or “an” may mean one or more than one.

[0039] The use of the term “or” in the claims is used to mean “and/or” unless explicitly indicated to refer to alternatives only or the alternatives are mutually exclusive, although the disclosure supports a definition that refers to only alternatives and “and/or.” As used herein “another” may mean at least a second or more.

5 [0040] Throughout this application, the term “about” is used to indicate that a value includes the inherent variation of error for the device, the method being employed to determine the value, or the variation that exists among the study subjects.

[0041] The term "cell" is herein used in its broadest sense in the art and refers to a living body that is a structural unit of tissue of a multicellular organism, is surrounded by a membrane  
10 structure that isolates it from the outside, has the capability of self-replicating, and has genetic information and a mechanism for expressing it. Cells used herein may be naturally-occurring cells or artificially modified cells (*e.g.*, fusion cells, genetically modified cells, *etc.*).

[0042] The term “stem cell” refers herein to a cell that under suitable conditions is capable of differentiating into a diverse range of specialized cell types, while under other  
15 suitable conditions is capable of self-renewing and remaining in an essentially undifferentiated pluripotent state. The term “stem cell” also encompasses a pluripotent cell, multipotent cell, precursor cell and progenitor cell. Exemplary human stem cells can be obtained from hematopoietic or mesenchymal stem cells obtained from bone marrow tissue, embryonic stem  
20 cells obtained from embryonic tissue, or embryonic germ cells obtained from genital tissue of a fetus. Exemplary pluripotent stem cells can also be produced from somatic cells by reprogramming them to a pluripotent state by the expression of certain transcription factors associated with pluripotency; these cells are called “induced pluripotent stem cells,” “iPS cells” or “iPSCs”.

[0043] An “embryonic stem (ES) cell” is an undifferentiated pluripotent stem cell  
25 which is obtained from an embryo in an early stage, such as the inner cell mass at the blastocyst stage, or produced by artificial means (*e.g.* nuclear transfer) and can give rise to any differentiated cell type in an embryo or an adult, including germ cells (*e.g.* sperm and eggs).

[0044] "Induced pluripotent stem cells (iPSCs)" are cells generated by reprogramming  
30 a somatic cell by expressing or inducing expression of a combination of factors (herein referred to as reprogramming factors). iPSCs can be generated using fetal, postnatal, newborn, juvenile, or adult somatic cells. In certain embodiments, factors that can be used to reprogram somatic

cells to pluripotent stem cells include, for example, Oct4 (sometimes referred to as Oct 3/4), Sox2, c-Myc, Klf4, Nanog, and Lin28. In some embodiments, somatic cells are reprogrammed by expressing at least two reprogramming factors, at least three reprogramming factors, or four reprogramming factors to reprogram a somatic cell to a pluripotent stem cell.

5           **[0045]** “Pluripotent stem cell” refers to a stem cell that has the potential to differentiate into all cells found in an organism preferably, cells representing any of the three germ layers: endoderm (*e.g.*, interior stomach lining, gastrointestinal tract, and the lungs), mesoderm (*e.g.*, muscle, bone, blood, and urogenital), or ectoderm (*e.g.*, epidermal tissues and nervous system).

10           **[0046]** As used herein, the term “somatic cell” refers to any cell other than germ cells, such as an egg or a sperm which does not directly transfer its DNA to the next generation. Typically, somatic cells have limited or no pluripotency. Somatic cells used herein may be naturally-occurring or genetically modified.

15           **[0047]** As used herein the term “engineered” in reference to cells refers to cells that comprise at least one genetic element exogenous to the cell that is integrated into the cell genome. In some aspects, the exogenous genetic element can be integrated at a random location in the cell genome. In other aspects, the genetic element is integrated at a specific site in the genome. For example, the genetic element may be integrated at a specific position to replace an endogenous nucleic acid sequence, such as to provide a change relative to the endogenous sequence (*e.g.*, a change in single nucleotide position).

20           **[0048]** A “precursor cell” as used herein refers to a stem cell which has the potential to differentiate into many different (pluri- and multipotent) or two different (bipotent) mature cell types. A precursor cell may also be a stem cell which has the capacity to differentiate into only one cell type. For example, precursor cells include neural precursor cells (NPCs), cardiomyocyte precursor cells and pancreatic precursor cells. “Neural precursor cells” are  
25 defined herein as immature cells of the nervous system which have the potential to develop into mature nervous system cells such as neurons and glia (*e.g.*, astrocytes and oligodendrocytes).

30           **[0049]** The term “suicide gene” refers to a gene whose protein product converts a non-toxic prodrug into a toxic drug (*e.g.*, an active chemotherapeutic agent), thereby killing cells that express the gene product.

[0050] As used herein, the term “polynucleotide” refers to a nucleic acid molecule that either is recombinant or has been isolated free of total genomic nucleic acid. By “isolated” when referring to a nucleotide sequence, is meant that the indicated molecule is present in the substantial absence of other biological macromolecules of the same type. Included within the term “polynucleotide” are recombinant vectors, including, for example, plasmids, cosmids, phage, viruses, and the like. Polynucleotides include, in certain aspects, regulatory sequences, isolated substantially away from their naturally occurring genes or protein coding sequences. Polynucleotides may be single-stranded (coding or antisense) or double-stranded, and may be RNA, DNA (*e.g.*, genomic DNA, cDNA, or synthetic DNA), analogs thereof, or a combination thereof. Additional coding or non-coding sequences may, but need not, be present within a polynucleotide.

[0051] The term “expression vector” refers to a vector containing a nucleic acid sequence coding for at least part of a gene product capable of being transcribed. In some cases, RNA molecules are then translated into a protein, polypeptide, or peptide. Expression vectors can contain a variety of “control sequences,” which refer to nucleic acid sequences necessary for the transcription and possibly translation of an operatively linked coding sequence in a particular host organism, including, but not limited to, promoter regions, polyadenylation signals, transcription termination sequences, upstream regulatory domains, internal ribosome entry sites (IRES), enhancers, and the like. In addition to control sequences that govern transcription and translation, vectors and expression vectors may contain nucleic acid sequences that serve other functions as well, such as origins of replication for the replication of a vector in a recipient cell. Not all of these control elements need always be present so long as the selected coding sequence is capable of being replicated, transcribed, and translated in an appropriate host cell.

[0052] The term “promoter region” is used herein in its ordinary sense to refer to a nucleotide region comprising a DNA regulatory sequence, wherein the regulatory sequence is derived from a gene that is capable of binding RNA polymerase and other transcription factors and initiating transcription of a downstream coding sequence. Promoter regions also control the rate of transcription. A promoter may or may not be used in conjunction with an “enhancer,” which refers to a *cis*-acting regulatory sequence involved in the transcriptional activation of a nucleic acid sequence. “Operatively linked” refers to an arrangement of elements wherein the components so described are configured so as to perform their usual

function. Thus, control sequences operatively linked to a coding sequence are capable controlling the transcriptional initiation and expression of that sequence. The control elements need not be contiguous with the coding sequence, so long as they function to direct the expression thereof. Thus, for example, intervening untranslated yet transcribed sequences can  
5 be present between a promoter sequence and the coding sequence and the promoter sequence can still be considered "operatively linked" to the coding sequence.

[0053] The term "heterologous," as it relates to nucleic acid sequences, such as gene sequences and control sequences, denotes sequences that are not normally joined together and/or are not normally associated with a particular cell. Thus, a "heterologous" region of a  
10 nucleic acid construct or a vector is a segment of nucleic acid within or attached to another nucleic acid molecule that is not found in association with the other molecule in nature. For example, a heterologous region of a nucleic acid construct could include a coding sequence flanked by sequences not found in association with the coding sequence in nature. Another example of a heterologous coding sequence is a construct where the coding sequence itself is  
15 not found in nature (*e.g.*, synthetic sequences having codons different from the native gene). Similarly, a cell transformed with a construct that is not normally present in the cell would be considered heterologous for purposes of the present disclosure. Allelic variation or naturally occurring mutational events do not give rise to heterologous DNA, as used herein.

[0054] For the purpose of describing the relative position of nucleotide sequences in a  
20 particular nucleic acid molecule throughout the present application, such as when a particular nucleotide sequence is described as being situated "upstream," "downstream," "5'," or "3'" relative to another sequence, it is to be understood that it is the position of the sequences in the non-transcribed strand of a DNA molecule that is being referred to as is conventional in the art.

[0055] "Homology" refers to the percent identity between two polynucleotide moieties.  
25 Two polynucleotide sequences are "substantially homologous" to each other when the sequences exhibit at least about 50%, preferably at least about 75%, more preferably at least about 80%-85%, preferably at least about 90%, and most preferably at least about 95%-98% sequence identity over a defined length of the molecules. As used herein, substantially homologous also refers to sequences showing complete identity to the specified polynucleotide  
30 sequence.



[0056] The term “transfection” is used to refer to the uptake of foreign DNA by a cell. A cell has been “transfected” when exogenous DNA has been introduced inside the cell membrane. A number of transfection techniques are generally known in the art. See, *e.g.*, Graham *et al.* (1973) *Virology*, 52:456, Sambrook *et al.* (1989) *Molecular Cloning*, a laboratory manual, Cold Spring Harbor Laboratories, New York, Davis *et al.* (1986) *Basic Methods in Molecular Biology*, Elsevier, and Chu *et al.* *Gene* 13: 197, 1981. Such techniques can be used to introduce one or more exogenous DNA moieties, such as a plasmid vector and other nucleic acid molecules, into suitable host cells. The term refers to both stable and transient uptake of the genetic material.

[0057] The term “transduction” denotes the delivery of a DNA molecule to a recipient cell either *in vivo* or *in vitro*, via a replication-defective viral vector, such as via a recombinant lentiviral vector particle.

[0058] By “vertebrate subject” is meant any member of the subphylum chordata, including, without limitation, mammals such as cattle, sheep, pigs, goats, horses, and human and non-human primates; domestic animals such as dogs and cats; laboratory animals including rodents such as mice, rats and guinea pigs, and the like; birds, including domestic, wild and game birds such as cocks and hens including chickens, turkeys and other gallinaceous birds; and fish. The term does not denote a particular age. Thus, both adult and newborn animals, as well as fetuses, are intended to be covered.

[0059] By “subject” or “patient” is meant any single subject for which therapy is desired, including humans, cattle, dogs, guinea pigs, rabbits, chickens, and so on. Also intended to be included as a subject are any subjects involved in clinical research trials not showing any clinical sign of disease, or subjects involved in epidemiological studies, or subjects used as controls.

[0060] Within the context of the present disclosure, the term “thymidine kinase mutant” should be understood to include not only the specific protein described herein (as well as the nucleic acid sequences which encode these proteins), but derivatives thereof which may include various structural forms of the primary protein which retain biological activity. For example, a thymidine kinase mutant may be in the form of acidic or basic salts, or in neutral form. In addition, individual amino acid residues may be modified by oxidation or reduction. Furthermore, various substitutions, deletions, or additions may be made to the amino acid or

nucleic acid sequences, the net effect of which is to retain or further enhance the increased biological activity of the mutant. Due to code degeneracy, for example, there may be considerable variation in nucleotide sequences encoding the same amino acid sequence.

## II. Cells of the Present Disclosure

5           **[0061]** In certain embodiments of the present disclosure, there are disclosed methods and compositions for producing precursor cells, such as neural precursor cells, comprising a construct with a cell-cycle dependent promoter operatively linked to a suicide gene, such as HSV-TK. In some aspects, the precursor cells are derived from a starting population of pluripotent stem cells (PSCs), such as embryonic stem cells or induced pluripotent stem cells.

### 10           A. Pluripotent Stem Cells

**[0062]** The starting population of PSCs of the present disclosure can be human embryonic stem cells (ESCs) or induced pluripotent stem cells (iPSC). Both ESCs and iPSCs are capable of long-term proliferation *in vitro*, while retaining the potential to differentiate into all cell types of the body, including neural precursor cells, cardiomyocytes, pancreatic beta  
15       cells, and hepatocytes. Certain aspects of the present disclosure concern precursor cells that could be induced directly from human ESC or iPSCs via expression of a combination of transcription factors for differentiation/function, similar to the generation of iPSCs, bypassing most, if not all, normal developmental stages.

#### 1. Embryonic Stem Cells

20           **[0063]** In certain aspects, the precursor cells are derived from ESCs. ESCs are derived from the inner cell mass of blastocysts and have a high *in vitro* differentiating capability. ESCs can be isolated by removing the outer trophectoderm layer of a developing embryo, then culturing the inner mass cells on a feeder layer of non-growing cells. The replated cells can continue to proliferate and produce new colonies of ESCs which can be removed, dissociated,  
25       replated again and allowed to grow. This process of “subculturing” undifferentiated ES cells can be repeated a number of times to produce cell lines containing undifferentiated ES cells (U.S. Patent Nos. 5,843,780; 6,200,806; 7,029,913). ESCs have the potential to proliferate while maintaining their pluripotency. For example, ESCs are useful in research on cells and on genes which control cell differentiation. The pluripotency of ESCs combined with genetic  
30       manipulation and selection can be used for gene analysis studies *in vivo* via the generation of transgenic, chimeric, and knockout mice.

[0064] Methods for producing mouse ESCs are well known. In one method, a preimplantation blastocyst from the 129 strain of mice is treated with mouse antiserum to remove the trophoectoderm, and the inner cell mass is cultured on a feeder cell layer of chemically inactivated mouse embryonic fibroblasts in medium containing fetal calf serum.

5 Colonies of undifferentiated ES cells that develop are subcultured on mouse embryonic fibroblast feeder layers in the presence of fetal calf serum to produce populations of ESCs. In some methods, mouse ESCs can be grown in the absence of a feeder layer by adding the cytokine leukemia inhibitory factor (LIF) to serum-containing culture medium (Smith, 2000). In other methods, mouse ESCs can be grown in serum-free medium in the presence of bone

10 morphogenetic protein and LIF (Ying *et al.*, 2003).

[0065] Human ESCs can be produced or derived from a zygote or blastocyst-staged mammalian embryo produced by the fusion of a sperm and egg cell, nuclear transfer, pathogenesis, or the reprogramming of chromatin and subsequent incorporation of the reprogrammed chromatin into a plasma membrane to produce an embryonic cell by previously

15 described methods (Thomson and Marshall, 1998; Reubinoff *et al.*, 2000). In one method, human blastocysts are exposed to anti-human serum, and trophectoderm cells are lysed and removed from the inner cell mass which is cultured on a feeder layer of mouse embryonic fibroblasts. Further, clumps of cells derived from the inner cell mass are chemically or mechanically dissociated, replated, and colonies with undifferentiated morphology are selected

20 by micropipette, dissociated, and replated. In some methods, human ESCs can be grown without serum by culturing the ESCs on a feeder layer of fibroblasts in the presence of basic fibroblast growth factor (Amit *et al.*, 2000). In other methods, human ESCs can be grown without a feeder cell layer by culturing the cells on a protein matrix such as MATRIGEL™ or laminin in the presence of “conditioned” medium containing basic fibroblast growth factor (Xu

25 *et al.*, 2001).

[0066] ESCs can also be derived from other organisms including rhesus monkey and marmoset by previously described methods (Thomson, and Marshall, 1998; Thomson *et al.*, 1995; Thomson and Odorico, 2000; U.S. Patent No. 5,843,780), as well as from established mouse and human cell lines. For example, established human ESC lines include MAOI, MA09,

30 ACT-4, HI, H7, H9, H13, H14 and ACT30. As a further example, mouse ESC lines that have been established include the CGR8 cell line established from the inner cell mass of the mouse

strain 129 embryos, and cultures of CGR8 cells can be grown in the presence of LIF without feeder layers.

[0067] ESCs can be detected by protein markers including transcription factor Oct4, alkaline phosphatase (AP), stage-specific embryonic antigen SSEA-1, stage-specific embryonic antigen SSEA-3, stage-specific embryonic antigen SSEA-4, transcription factor NANOG, tumor rejection antigen 1-60 (TRA-1-60), tumor rejection antigen 1-81 (TRA-1-81), SOX2, or REX1.

## 2. Induced Pluripotent Stem Cells

[0068] In other aspects, the precursor cells are derived from induced pluripotent stem cells, commonly abbreviated iPS cells or iPSCs. The induction of pluripotency was originally achieved in 2006 using mouse cells (Yamanaka *et al.* 2006) and in 2007 using human cells (Yu *et al.* 2007; Takahashi *et al.* 2007) by reprogramming of somatic cells via the introduction of transcription factors that are linked to pluripotency. The use of iPSCs circumvents most of the ethical and practical problems associated with large-scale clinical use of ES cells, and patients with iPSC-derived autologous transplants may not require lifelong immunosuppressive treatments to prevent graft rejection.

[0069] With the exception of certain cell types (such as germ cells and enucleated erythrocytes), any cell can be used as a starting point for iPSCs. For example, cell types could be neurons, keratinocytes, fibroblasts, hematopoietic cells, mesenchymal cells, liver cells, or stomach cells. There is no limitation on the degree of cell differentiation or the age of an animal from which cells are collected; even undifferentiated progenitor cells (including somatic stem cells) and finally differentiated mature cells can be used as sources of somatic cells in the methods disclosed herein. The somatic cell can be an adult or a fetal somatic cell. iPSCs can be grown under conditions that are known to differentiate human ESCs into specific cell types, and express human ESC markers including: SSEA-1, SSEA-3, SSEA-4, TRA-1-60, and TRA-1-81.

[0070] Somatic cells can be reprogrammed to produce induced pluripotent stem cells (iPSCs) using methods known to one of skill in the art. One of skill in the art can readily produce induced pluripotent stem cells, see for example, U.S. Patent Publication Nos. 20090246875, 201000210014; 20120276636; U.S. Patent Nos. 8,058,065, 8,129,187, 8,278,620, 8,268,630; and PCT Publication No. WO 2007069666, which are incorporated

herein by reference. Generally, nuclear reprogramming factors are used to produce pluripotent stem cells from a somatic cell. Reprogramming factors known in the art include Klf4, c-Myc, Oct3/4, Sox2, Nanog, and Lin28. Any combination of factors may be used in the present methods.

5           **[0071]** Mouse and human cDNA sequences of these nuclear reprogramming substances are available with reference to the NCBI accession numbers mentioned in U.S. Patent No. 8,183,038 and PCT Publication No. WO 2007069666, which are incorporated herein by reference. Methods for introducing one or more reprogramming substances, or nucleic acids encoding these reprogramming substances, are known in the art, and disclosed for example, in  
10 published U.S. Patent Nos. 8,071,369, 8,268,620, 8,691,574, 8,741,648, 8,546,140, 8,900,871 and 9,175,268, which are incorporated herein by reference.

**[0072]** Once derived, iPSCs can be cultured in a medium sufficient to maintain pluripotency. The iPSCs may be used with various media and techniques developed to culture pluripotent stem cells, more specifically, embryonic stem cells, as described in U.S. Patent No.  
15 7,442,548 and U.S. Patent Publication. No. 20030211603. In the case of mouse cells, the culture may be carried out with the addition of Leukemia Inhibitory Factor (LIF) as a differentiation suppression factor to an ordinary medium. In the case of human cells, basic fibroblast growth factor (bFGF) may be added in place of LIF. Other methods for the culture and maintenance of iPSCs, as would be known to one of skill in the art, may be used with the  
20 present disclosure.

**[0073]** In certain embodiments, undefined conditions may be used; for example, pluripotent cells may be cultured on fibroblast feeder cells or a medium that has been exposed to fibroblast feeder cells in order to maintain the stem cells in an undifferentiated state. In some  
25 embodiments, the cell is cultured in the co-presence of mouse embryonic fibroblasts treated with radiation or an antibiotic to terminate the cell division, as feeder cells. Alternately, pluripotent cells may be cultured and maintained in an essentially undifferentiated state using a defined, feeder-independent culture system, such as a TESR™ medium (Ludwig *et al.*, 2006a; Ludwig *et al.*, 2006b) or E8™ /Essential 8™ medium (Chen *et al.*, 2011).

**[0074]** Plasmids have been designed with a number of goals in mind, such as achieving  
30 regulated high copy number and avoiding potential causes of plasmid instability in bacteria, and providing means for plasmid selection that are compatible with use in mammalian cells,

including human cells. Particular attention has been paid to the dual requirements of plasmids for use in human cells. First, they are suitable for maintenance and fermentation in *E. coli*, so that large amounts of DNA can be produced and purified. Second, they are safe and suitable for use in human patients and animals. The first requirement calls for high copy number plasmids that can be selected for and stably maintained relatively easily during bacterial fermentation. The second requirement calls for attention to elements such as selectable markers and other coding sequences. In some embodiments, plasmids that encode a marker are composed of: (1) a high copy number replication origin, (2) a selectable marker, such as, but not limited to, the neo gene for antibiotic selection with kanamycin, (3) transcription termination sequences, including the tyrosinase enhancer and (4) a multicloning site for incorporation of various nucleic acid cassettes; and (5) a nucleic acid sequence encoding a marker operably linked to the tyrosinase promoter. There are numerous plasmid vectors that are known in the art for inducing a nucleic acid encoding a protein. These include, but are not limited to, the vectors disclosed in U.S. Patent No. 6,103,470; U.S. Patent No. 7,598,364; U.S. Patent No. 7,989,425; and U.S. Patent No. 6,416,998, which are incorporated herein by reference.

[0075] An episomal gene delivery system can be a plasmid, an Epstein-Barr virus (EBV)-based episomal vector (U.S. Patent 8,546,140), a yeast-based vector, an adenovirus-based vector, a simian virus 40 (SV40)-based episomal vector, a bovine papilloma virus (BPV)-based vector, or a lentiviral vector. A viral gene delivery system can be an RNA-based or DNA-based viral vector (PCT/JP2009/062911, PCT/JP2011/069588; incorporated herein by reference).

### 3. Embryonic Stem Cells Derived by Somatic Cell Nuclear Transfer

[0076] Pluripotent stem cells for deriving the starting population of host cells could also be prepared by means of somatic cell nuclear transfer, in which a donor nucleus is transferred into a spindle-free oocyte. Stem cells produced by nuclear transfer are genetically identical to the donor nuclei. In one method, donor fibroblast nuclei from skin fibroblasts of a rhesus macaque are introduced into the cytoplasm of spindle-free, mature metaphase II rhesus macaque oocytes by electrofusion (Byrne *et al.*, 2007). The fused oocytes are activated by exposure to ionomycin, then incubated until the blastocyst stage. The inner cell mass of selected blastocysts are then cultured to produce embryonic stem cell lines. The embryonic stem cell

lines show normal ES cell morphology, express various ES cell markers, and differentiate into multiple cell types both *in vitro* and *in vivo*.

### **B. Precursor Cells**

[0077] Certain embodiments of the present disclosure concern precursor cells comprising a vector encoding a suicide gene under the control of a cell-cycle dependent promoter. The precursor cells may be differentiated from PSCs. Exemplary precursor cells include neural precursor cells (NPCs), cardiomyocyte precursor cells and pancreatic precursor cells.

[0078] Neural precursor cells may be differentiated from PSCs using methods known in the art such as, but not limited to, the method disclosed in U.S. Patent No. 7,968,337; incorporated herein by reference. In brief, the PSCs are cultured in a first medium comprising basic fibroblast growth factor (bFGF), a second medium comprising bFGF and epidermal growth factor (EGF), and a third medium comprising bFGF and platelet-derived growth factor (PDGF) to obtain neural precursor cells. The NPCs can be detected and/or isolated using markers such as musashi, nestin, sox2, vimentin, pax6, and sox1. The NPCs can also be further differentiated to express a variety of neuronal markers, *e.g.*, MAP2, beta-III-tubulin, synapsin, cholinacetyltransferase, tyrosin hydroxylase, GABA, glutamate, serotonin, peripherin and calbindin. Maturation and survival of the differentiated neurons can be enhanced by addition of neurotrophins, *e.g.*, BDNF or neurotrophin 3 (NT-3). Additional methods for the production and culturing of NPCs can be found, for example, in U.S. Patent Nos. 8,093,053; 5,980,885; 7,968,337 and 8,178,349 and U.S. Application No. 20100323444; each of which is incorporated herein by reference.

### **III. Polynucleotides of the Present Disclosure**

[0079] In certain embodiments, the present disclosure concerns isolated and recombinant polynucleotides, such as polynucleotides comprising a cell cycle-dependent promoter operatively linked to a suicide gene. In particular embodiments, the present disclosure concerns isolated nucleic acids and recombinant vectors incorporating nucleic acid sequences that encode a suicide gene, the expression of which is operatively linked to a cell cycle-dependent promoter. The term “recombinant” may be used in conjunction with a polynucleotide or polypeptide and generally refers to a polypeptide or polynucleotide produced and/or manipulated *in vitro* or that is a replication product of such a molecule.

[0080] A nucleic acid may be made by any technique known to one of ordinary skill in the art. Non-limiting examples of a synthetic nucleic acid, particularly a synthetic oligonucleotide, include a nucleic acid made by *in vitro* chemical synthesis using phosphotriester, phosphite or phosphoramidite chemistry and solid phase techniques such as described in EP 266,032, or via deoxynucleoside H-phosphonate intermediates as described by Froehler *et al.*, 1986, and U.S. Patent No. 5,705,629. A non-limiting example of enzymatically produced nucleic acid includes one produced by enzymes in amplification reactions such as PCR™ (see for example, U.S. Patent No. 4,683,202 and U.S. Patent No. 4,682,195 ), or the synthesis of oligonucleotides described in U.S. Patent No. 5,645,897. A non-limiting example of a biologically produced nucleic acid includes recombinant nucleic acid production in living cells, such as recombinant DNA vector production in bacteria (see for example, Sambrook *et al.* 1989).

[0081] The nucleic acids used in the present disclosure can be combined with other nucleic acid sequences, such as promoters, polyadenylation signals, additional restriction enzyme sites, multiple cloning sites, other coding segments, and the like, such that their overall length may vary considerably. It is therefore contemplated that a nucleic acid fragment of almost any length may be employed, with the total length preferably being limited by the ease of preparation and use in the intended recombinant nucleic acid protocol.

#### A. Nucleic Acid Delivery

[0082] The polynucleotides of the present disclosure may be introduced (*e.g.*, transfected or transduced) into a host cell by viral or non-viral methods. Vectors provided herein are designed, primarily, to express a suicide gene under the control of a cell-cycle dependent promoter. One of skill in the art would be well-equipped to construct a vector through standard recombinant techniques (see, for example, Sambrook *et al.*, 2001 and Ausubel *et al.*, 1996, both incorporated herein by reference). Vectors include but are not limited to, plasmids, cosmids, viruses (*e.g.*, bacteriophage, animal viruses, and plant viruses), artificial chromosomes (*e.g.*, YACs), retroviral vectors (*e.g.* derived from Moloney murine leukemia virus vectors (MoMLV), MSCV, SFFV, MPSV, SNV *etc.*), lentiviral vectors (*e.g.* derived from HIV-1, HIV-2, SIV, BIV, FIV *etc.*), adenoviral (Ad) vectors including replication competent, replication deficient and gutless forms thereof, adeno-associated viral (AAV) vectors, simian virus 40 (SV-40) vectors, bovine papilloma virus vectors, Epstein-Barr virus vectors, herpes virus vectors, vaccinia virus vectors, Harvey murine sarcoma virus vectors, murine mammary



tumor virus vectors, Rous sarcoma virus vectors, parvovirus vectors, polio virus vectors, vesicular stomatitis virus vectors, maraba virus vectors and group B adenovirus enadenotucirev vectors.

## 1. Viral Vectors

5 [0083] Viral vectors encoding a cell cycle-dependent promoter operatively linked to a suicide gene may be provided in certain aspects of the present disclosure. In generating recombinant viral vectors, non-essential genes are typically replaced with a gene or coding sequence for a heterologous (or non-native) protein. A viral vector is a kind of expression construct that utilizes viral sequences to introduce nucleic acid and possibly proteins into a cell.

10 The ability of certain viruses to infect cells or enter cells via receptor-mediated endocytosis, and to integrate into host cell genomes and express viral genes stably and efficiently have made them attractive candidates for the transfer of foreign nucleic acids into cells (*e.g.*, mammalian cells). Non-limiting examples of virus vectors that may be used to deliver a nucleic acid of certain aspects of the present disclosure are described below. "Recombinant viral vectors" in

15 the present disclosure refers to viral vectors constructed by genetic recombination techniques. Viral vectors constructed using packaging cells and DNAs encoding a viral genome are called recombinant viral vectors.

### i. Retroviral vectors

[0084] In one aspect of the present disclosure, retroviral constructs are provided

20 comprising a 5' long terminal repeat (LTR), a tRNA binding site, a packaging signal, one or more heterologous sequences, an origin of second strand DNA synthesis and a 3' LTR, wherein the vector construct lacks gag/pol and/or env coding sequences.

[0085] Heterologous sequences that are included in the vector construct are those that encode a protein, preferably a suicide gene, such as herpes simplex virus thymidine kinase.

25 Within certain embodiments of the present disclosure, the expression cassette described herein may be contained within a plasmid construct.

[0086] A retroviral vector of the present disclosure includes at least one expression cassette, which is an assembly that is capable of directing the expression of the sequence(s) or gene(s) of interest. The expression cassette includes a transcriptional promoter region or promoter/enhancer that is operatively linked to the sequence(s) or gene(s) of interest, and may

30 include a polyadenylation sequence as well. Such vector constructs also include a packaging

signal, LTRs or functional portions thereof, and positive and negative strand primer binding sites appropriate to the retrovirus used. Optionally, the recombinant retroviral vector may also include a selectable and/or non-selectable marker, an origin of second strand DNA synthesis, a signal that allows the plasmid construct to exist as single-stranded DNA (*e.g.*, a M13 origin of replication), a bacterial origin of replication, and a mammalian origin of replication (*e.g.*, a SV40 or adenovirus origin of replication), one or more restriction sites, and a translation termination sequence. Examples of selectable and non-selectable markers include, but are not limited to, neomycin (Neo), thymidine kinase (TK), hygromycin, phleomycin, puromycin, histidinol, green fluorescent protein (GFP), human placental alkaline phosphatase (PLAP), DHFR,  $\beta$ -galactosidase, and human growth hormone (hGH).

**[0087]** In retroviruses, the LTR may also be modified. The LTR is a retrovirus-specific sequence, which is present at both ends of the viral genome. The 5' LTR serves as a promoter, enhancing proviral mRNA transcription. Thus, it may be possible to enhance mRNA transcription of the gene transfer vector, improve packaging efficiency, and increase vector titer if the portion exhibiting the 5' LTR promoter activity in the gene transfer vector is substituted with another promoter having stronger promoter activity. Furthermore, for example, in the case of lentiviruses, the viral protein *tat* is known to enhance 5' LTR transcription activity, and therefore, substitution of the 5' LTR with a promoter independent of the *tat* protein will enable the exclusion of *tat* from the packaging vectors. After RNAs of viruses that have infected or invaded cells are reverse transcribed, the LTRs at both ends are linked to form a closed circular structure, viral integrase couples with the linkage site, and this structure is then integrated into cell chromosomes. The transcribed proviral mRNAs consist of the region ranging from the 5' LTR transcription initiation site to the 3' LTR polyadenylation sequence located downstream. The 5' LTR promoter portion is not packaged in the virus. Thus, even if the promoter is replaced with another sequence, the portion integrated into target cell chromosomes is unchanged. Based on the facts described above, substitution of the 5' LTR promoter is thought to provide a safer vector with a higher titer. Thus, substitution of the promoter at the 5' end of a gene transfer vector can increase the titer of a packageable vector.

**[0088]** Safety can be improved in recombinant retroviral virus vectors by preventing transcription of the full-length vector mRNA in target cells. This is achieved using a self-inactivating vector (SIN vector) prepared by partially eliminating the 3' LTR sequence. The provirus that has invaded the target cell chromosomes has its 5' end bound to the U3 portion of

its 3' LTR. Thus, the U3 portion is located at the 5' end in the gene transfer vector, and from that point, the entire RNA of the gene transfer vector is transcribed. If there are retroviruses or similar proteins in target cells, it is possible that the gene transfer vector may be re-packaged and infect other cells. There is also a possibility that the 3' LTR promoter may express host genes located downstream of the viral genome. When the 3' LTR U3 portion is deleted from a gene transfer vector, target cells lack the promoters of 5' LTR and 3' LTR, thereby preventing the transcription of the full-length viral RNA and host genes. Furthermore, since only the genes of interest are transcribed from endogenous promoters, highly safe vectors capable of high expression can be expected. Such vectors are preferable in the present disclosure. SIN vectors can be constructed according to known methods.

**[0089]** SIN vectors have the added advantage of overcoming the gradual decrease in expression of introduced genes resulting from host methylation of LTR sequences after integration (Challita, P. M. and Kohn, D. B., Proc. Natl. Acad. Sci. USA 91: 2567, 1994). LTR methylation hardly reduces gene expression level in SIN vectors. This is because the vector loses most of the LTR sequence upon integration into the host genome. A SIN vector prepared by substituting another promoter sequence for the 3' LTR U3 region of a gene transfer vector was found to maintain a stable expression for more than two months after introduction into primate ES cells (WO 02/101057). Thus, a SIN vector designed to self-inactivate by the modification of the LTR U3 region may be used in the present disclosure.

**[0090]** Retroviruses can be produced by transcribing in host cells gene transfer vector DNAs which contain a packaging signal and forming virus particles in the presence of gag, pol and envelope proteins. The packaging signal sequence encoded by the gene transfer vector DNAs should preferably be sufficient in length to maintain the structure formed by the sequence. However, in order to suppress the frequency of wild-type virus formation, which occurs due to recombination of the vector DNA packaging signal and the packaging vector supplying the gag and pol proteins, it is also necessary to keep sequence overlapping between these vector sequences to a minimum. Therefore, when it comes to the construction of the gene transfer vector DNAs, it is preferable to use a sequence which is as short as possible and yet still contains the sequence essential for packaging, to ensure packaging efficiency and safety.

**[0091]** The SIV vectors may be replication-incompetent viruses from which 40% or more, more preferably 50% or more, still more preferably 60% or more, even more preferably

70% or more, and most preferably 80% or more of the sequence derived from the original SIV genome has been removed.

[0092] In a gene transfer vector DNA, the gag protein has been modified such that it is not expressed. Viral gag protein may be detected by a living body as a foreign substance, and thus as a potential antigen. Alternatively, the protein may affect cellular functions. To prevent gag protein expression, nucleotides downstream of the gag start codon can be added or deleted, introducing modifications which will cause a frameshift. It is also preferable to delete portions of the coding region of the gag protein. The 5' portion of the coding region of the gag protein is known to be essential for virus packaging. Thus, in a gene transfer vector, it is preferable that the C-terminal side of the gag protein-coding region has been deleted. It is preferable to delete as large a portion of the gag coding region as possible, so long as the deletion does not considerably affect the packaging efficiency. It is also preferable to replace the start codon (ATG) of the gag protein with a codon other than ATG. The replacement codon can be selected appropriately so as not to greatly affect the packaging efficiency. A viral vector can be produced by introducing the constructed gene transfer vector DNA, which comprises the packaging signal, into appropriate packaging cells. The viral vector produced can be recovered from, for example, the culture supernatant of packaging cells.

[0093] "Packaging cell" refers to a cell that contains those elements necessary for production of infectious recombinant retrovirus that are lacking in a recombinant retroviral vector. Packaging cells contain one or more expression cassettes that are capable of expressing proteins that encode gag, pol, and env-derived proteins. Packaging cells can also contain expression cassettes encoding one or more of vif, rev, or ORF 2 in addition to gag/pol and env expression cassettes.

[0094] There is no limitation on the type of packaging cell, as long as the cell line is generally used in viral production. When used for human gene therapy, a human- or monkey-derived cell is suitable. Human cell lines that can be used as packaging cells include, for example, 293 cells, 293T cells, 293EBNA cells, SW480 cells, u87MG cells, HOS cells, C8166 cells, MT-4 cells, Molt-4 cells, HeLa cells, HT1080 cells, and TE671 cells. Monkey cell lines include, for example, COS1 cells, COS7 cells, CV-1 cells, and BMT10 cells.

[0095] Lentiviruses are complex retroviruses, which, in addition to the common retroviral genes *gag*, *pol*, and *env*, contain other genes with regulatory or structural function.

Lentiviral vectors are well known in the art (see, for example, Naldini *et al.*, 1996; Zufferey *et al.*, 1997; Blomer *et al.*, 1997; U.S. Patents 6,013,516 and 5,994,136). Recombinant lentiviral vectors are capable of infecting non-dividing cells and can be used for both *in vivo* and *ex vivo* gene transfer and expression of nucleic acid sequences. For example, recombinant lentivirus  
5 capable of infecting a non-dividing cell— wherein a suitable host cell is transfected with two or more vectors carrying the packaging functions, namely gag, pol and env, as well as rev and tat—is described in U.S. Patent 5,994,136, incorporated herein by reference.

[0096] The pseudotyped lentiviral vectors of the present disclosure can be purified to become substantially pure. The phrase "substantially pure" means that the pseudotyped  
10 lentiviral vectors contain substantially no replicable virus other than the lentivirus. The purification can be achieved using known purification and separation methods such as filtration, centrifugation, and column purification. For example, a vector can be precipitated and concentrated by filtering a vector solution with a 0.45- $\mu\text{m}$  filter, and then centrifuging it at 42500 x g at 4°C for 90 minutes. If necessary, the pseudotyped lentiviral vectors of the present  
15 disclosure can be prepared as compositions by appropriately combining with desired pharmaceutically acceptable carriers or vehicle. Specifically, the vector can be appropriately combined with, for example, sterilized water, physiological saline, culture medium, serum, and phosphate buffered saline (PBS). The vector can also be combined with a stabilizer, biocide, and such. Compositions containing a pseudotyped lentiviral vector of the present disclosure are  
20 useful as reagents or pharmaceuticals. For example; compositions of the present disclosure can be used as reagents for gene transfer into airway stem cells, or as pharmaceuticals for gene therapy of various diseases such as genetic diseases.

[0097] Within one aspect of the present disclosure, retroviral gene delivery vehicles are provided that are constructed to carry or express a selected gene(s) or sequence(s) of interest.  
25 Briefly, retroviral gene delivery vehicles of the present disclosure may be readily constructed from a wide variety of retroviruses, including, for example, B, C, and D type retroviruses as well as spumaviruses and lentiviruses, such as FIV, HIV-1, HIV-2, EIAV, and SIV (see RNA Tumor Viruses, Second Edition, Cold Spring Harbor Laboratory, 1985). Such retroviruses may be readily obtained from depositories or collections, such as the American Type Culture  
30 Collection ("ATCC"; 10801 University Blvd., Manassas, VA 20110-2209), or isolated from known sources using commonly available techniques. Any of the above retroviruses may be readily utilized in order to assemble or construct retroviral gene delivery vehicles given the

disclosure provided herein, and standard recombinant techniques (*e.g.*, Sambrook *et al.*, Molecular Cloning: A Laboratory Manual, 2d ed., Cold Spring Harbor Laboratory Press, 1989; Kunkle, *PNAS* 52:488, 1985). In addition, within certain embodiments of the present disclosure, portions of the retroviral gene delivery vehicles may be derived from different retroviruses. For example, within one embodiment of the present disclosure, retroviral LTRs  
5 may be derived from a murine sarcoma virus, a tRNA binding site from a Rous sarcoma virus, a packaging signal from a murine leukemia virus, and an origin of second strand synthesis from an avian leukosis virus.

[0098] Within certain embodiments of the present disclosure, retroviral vectors are provided wherein viral promoters, preferably CMV or SV40 promoters and/or enhancers are utilized to drive expression of one or more genes of interest. Within other aspects of the present disclosure, retroviral vectors are provided wherein tissue-specific promoters are utilized to drive expression of one or more genes of interest.  
10

[0099] Retrovirus vector constructs for use with the present disclosure may be generated such that more than one gene of interest is expressed and preferably secreted. This may be accomplished through the use of di- or oligo-cistronic cassettes (*e.g.*, where the coding regions are separated by 120 nucleotides or less, see generally Levin *et al.*, *Gene* 108:167-174, 1991), or through the use of internal ribosome entry sites ("IRES").  
15

[00100] Within one aspect of the present disclosure, self-inactivating (SIN) vectors are made by deleting promoter and enhancer elements in the U3 region of the 3' LTR, including the TATA box, and binding sites for one or more transcription factors. The deletion is transferred to the 5' LTR after reverse transcription and integration in transduced cells. This results in the transcriptional inactivation of the LTR in the provirus. Possible advantages of SIN vectors include increased safety of the gene delivery system as well as the potential to reduce promoter interference between the LTR and the internal promoter, which may result in increased expression of the gene of interest. Furthermore, it is reasonable to expect tighter control of inducible gene therapy vectors due to the lack of an upstream promoter element in the 5' LTR.  
20  
25

[00101] Within one aspect of the present disclosure, lentiviral vector constructs are provided comprising a 5' LTR, a tRNA binding site, a packaging signal, one or more heterologous sequences, an origin of second strand DNA synthesis, an RNA export element,  
30

and a 3' LTR. Briefly, long terminal repeats ("LTRs") are subdivided into three elements, designated U5, R, and U3. These elements contain a variety of signals that are responsible for the biological activity of a retrovirus, including for example, promoter and enhancer elements that are located within U3. LTRs may be readily identified in the provirus (integrated DNA  
5 form) due to their precise duplication at either end of the genome. For purposes of the present disclosure, a 5' LTR should be understood to include as much of the native 5' LTR as is required to function as a 5' promoter or promoter/enhancer element, to allow reverse transcription, and to allow integration of the DNA form of the vector. The 3' LTR should be understood to include  
10 as much of the 3' FIV LTR as is required to function as a polyadenylation signal, to allow reverse transcription, and to allow integration of the DNA form of the vector.

**[00102]** Additionally, retroviral vectors may contain hybrid LTRs where up to 75% of the wild-type LTR sequence is deleted and replaced by one or more viral or non-viral promoter or promoter/enhancer elements (*e.g.*, other retroviral LTRs and/or non-retroviral promoters or promoter/enhancers such as the CMV promoter/enhancer or the SV40 promoter)  
15 similar to the hybrid LTRs described by Chang, *et al.*, *J. Virology* 67, 743-752, 1993; Finer, *et al.*, *Blood* 83, 43-50, 1994 and Robinson, *et al.*, *Gene Therapy* 2, 269-278, 1995.

**[00103]** The tRNA binding site and origin of second strand DNA synthesis are also important for a retrovirus to be biologically active, and may be readily identified by one of skill in the art. For example, tRNA binds to a retroviral tRNA binding site by Watson-Crick base  
20 pairing, and is carried with the retrovirus genome into a viral particle. The tRNA is then utilized as a primer for DNA synthesis by reverse transcriptase. The tRNA binding site may be readily identified based upon its location just downstream from the 5' LTR. Similarly, the origin of second strand DNA synthesis is, as its name implies, important for the second strand DNA synthesis of a retrovirus. This region, which is also referred to as the poly-purine tract, is  
25 located just upstream of the 3' LTR.

**[00104]** In addition to 5' and 3' LTRs, a tRNA binding site, a packaging signal, and an origin of second strand DNA synthesis, certain preferred recombinant retroviral vector constructs for use herein also comprise one or more genes of interest. In addition, the retroviral vectors may, but need not, include an RNA export element (also variously referred to as RNA  
30 transport, nuclear transport or nuclear export elements) that may be a RRE (Rev-responsive element) or a heterologous transport element. Representative examples of suitable heterologous RNA export elements include the Mason-Pfizer monkey virus constitutive

transport element (Bray *et al.*, *PNAS USA* 91, 1256-1260, 1994), the hepatitis B virus posttranscriptional regulatory element (Huang *et al.*, *Mol Cell. Biol.* 73:7476-7486, 1993 and Huang *et al.*, *J. Virology* 65:3193-3199, 1994), or lentiviral Rev-responsive elements (Daly *et al.*, *Nature* 342:816-819, 1989 and Zapp *et al.*, *Nature* 342:714-716, 1989).

5           **[00105]** Retroviral vector constructs that lack both gag/pol and env coding sequences may be used with the present disclosure. As utilized herein, the phrase "lacks gag/pol or env coding sequences" should be understood to mean that the vector contains less than 20, preferably less than 15, more preferably less than 10, and most preferably less than 8 consecutive nucleotides that are found in gag/pol or env genes, and in particular, within gag/pol  
10 or env expression cassettes that are used to construct packaging cell lines for the retroviral vector construct. This aspect of the present disclosure provides for retroviral vectors having a low probability of undesirable recombination with gag/pol or env sequences that may occur in a host cell or be introduced therein, for example, by transformation with an expression cassette. The production of retroviral vector constructs lacking gag/pol or env sequences may be  
15 accomplished by partially eliminating the packaging signal and/or the use of a modified or heterologous packaging signal. Within other embodiments of the present disclosure, retroviral vector constructs are provided wherein a portion of the packaging signal that may extend into, or overlap with, the retroviral gag/pol sequence is modified (*e.g.*, deleted, truncated, or bases exchanged). Within other aspects of the present disclosure, retroviral vector constructs are  
20 provided that include the packaging signal that may extend beyond the start of the gag/pol gene. Within certain embodiments, the packaging signal that may extend beyond the start of the gag/pol gene is modified in order to contain one, two, or more stop codons within the gag/pol reading frame. Most preferably, one of the stop codons eliminates the gag/pol start site. In other embodiments, the introduced mutation may cause a frame shift in the gag/pol coding  
25 region.

**[00106]** Other retroviral gene delivery vehicles may likewise be utilized within the context of the present disclosure, including for example those described in EP 0,415,731; WO 90/07936; WO 91/0285, WO 9403622; WO 9325698; WO 9325234; U.S. Patent No. 5,219,740; WO 9311230; WO 9310218; Vile and Hart, *Cancer Res.* 53:3860-3864, 1993; Vile and Hart, *Cancer Res.* 53:962-967, 1993; Ram *et al.*, *Cancer Res.* 53:83-88, 1993; Takamiya  
30 *et al.*, *J. Neurosci. Res.* 33:493-503, 1992; Baba *et al.*, *J. Neurosurg.* 79:729- 735, 1993 (U.S. Patent No. 4,777,127, GB 2,200,651, EP 0,345,242 and WO91/02805).



[00107] Packaging cell lines suitable for use with the above described retroviral constructs may be readily prepared (see, *e.g.*, U.S. Patent Nos. 5,591,624 and 6,013,517; and International Publication No. WO 95/30763), and utilized to create producer cell lines for the production of recombinant vector particles. The parent cell line from which the packaging cell  
5 line is derived can be selected from a wide variety of mammalian cell lines, including for example, human cells, monkey cells, feline cells, dog cells, mouse cells, and the like.

[00108] After selection of a suitable host cell for the generation of a packaging cell line, one or more expression cassettes are introduced into the cell line in order to complement or supply in *trans* components of the vector which have been deleted (see, *e.g.*, U.S. Patent  
10 Nos. 5,591,624 and 6,013,517, incorporated herein by reference in their entireties; and International Publication No. WO 95/30763). For example, packaging expression cassettes may encode either gag/pol sequences alone, gag/pol sequences and one or more of vif, rev, or ORF 2, or one or more of vif, rev, or ORF 2 alone and may contain an RNA export element. For example, the packaging cell line may contain only ORF 2, vif, or rev alone, ORF 2 and vif,  
15 ORF 2 and rev, vif and rev, or all three of ORF 2, vif and, rev.

[00109] Packaging cell lines may also comprise a promoter and a sequence encoding ORF 2, vif, rev, or an envelope (*e.g.*, VSV-G), wherein the promoter is operatively linked to the sequence encoding ORF 2, vif, rev, or the envelope. For packaging cell lines containing inducible gag/pol or env expression cassettes, additional expression cassettes facilitating the  
20 transactivation of the inducible promoter may be incorporated. The expression cassette may or may not be stably integrated. The packaging cell line, upon introduction of a retroviral vector, may produce particles at a concentration of greater than 10<sup>3</sup>, 10<sup>4</sup>, 10<sup>5</sup>, 10<sup>6</sup>, 10<sup>7</sup>, 10<sup>8</sup>, or 10<sup>9</sup> cfu/mL.

## ii. Lentiviral vectors

[00110] "Lentivirus" refers to a virus belonging to the lentivirus genus. Lentiviruses include, but are not limited to, human immunodeficiency virus (HIV) (for example, HIV-1 or HIV-2), simian immunodeficiency virus (SIV), feline immunodeficiency virus (FIV), Maedi-Visna-like virus (EV1), equine infectious anemia virus (EIAV) and caprine arthritis encephalitis virus (CAEV).

[00111] The terms "lentiviral vector construct," "lentiviral vector," and "recombinant lentiviral vector" are used interchangeably herein and refer to a nucleic acid

construct derived from a lentivirus that carries and, within certain embodiments, is capable of directing the expression of a nucleic acid molecule of interest. Lentiviral vectors can have one or more of the lentiviral wild-type genes deleted in whole or part but retain functional flanking long-terminal repeat (LTR) sequences. The LTRs need not be the wild-type nucleotide sequences, and may be altered, *e.g.*, by the insertion, deletion or substitution of nucleotides, so long as the sequences provide for functional rescue, replication, and packaging. The lentiviral vector may also contain a selectable marker.

[00112] The term “recombinant lentivirus” refers to a virus particle that contains a lentivirus-derived viral genome, lacks the self-renewal ability, and has the ability to introduce a nucleic acid molecule into a host. For example, the recombinant lentiviruses of the present disclosure include virus particles comprising a nucleic acid molecule that comprises a lentiviral genome-derived packaging signal sequence. The recombinant lentivirus is capable of reverse transcribing its genetic material into DNA and incorporating this genetic material into a host cell's DNA upon infection. Recombinant lentivirus particles may have a lentiviral envelope, a non-lentiviral envelope (*e.g.*, an amphotropic or VSV-G envelope), a chimeric envelope, or a modified envelope (*e.g.*, truncated envelopes or envelopes containing hybrid sequences).

[00113] A nucleic acid carried by a lentiviral vector of the present disclosure can be introduced into pluripotent stem cells or neural progenitor cells by contacting this vector with pluripotent stem cells of primates, including humans, or rodents, including mice and rats. The present disclosure relates to methods for introducing suicide genes into pluripotent stem cells, which comprise the step of contacting pluripotent stem cells with the vectors of the present disclosure. The pluripotent stem cells targeted for gene introduction are not particularly limited and, for example, include embryonic stem cells or induced pluripotent stem cells.

### iii. **Adenoviral Vector**

[00114] The polynucleotide encoding a cell-cycle dependent promoter operatively linked to a suicide gene may be provided in an adenoviral vector. Although adenovirus vectors are known to have a low capacity for integration into genomic DNA, this feature is counterbalanced by the high efficiency of gene transfer afforded by these vectors. Adenovirus expression vectors include constructs containing adenovirus sequences sufficient to (a) support packaging of the construct and (b) to ultimately express a recombinant gene construct that has been cloned therein.

[00115] Adenovirus growth and manipulation is known to those of skill in the art, and exhibits broad host range *in vitro* and *in vivo*. This group of viruses can be obtained in high titers, *e.g.*, 10<sup>9</sup>-10<sup>11</sup> plaque-forming units per ml, and they are highly infective. The life cycle of adenovirus does not require integration into the host cell genome. The foreign genes  
5 delivered by adenovirus vectors are episomal and, therefore, have low genotoxicity to host cells. No side effects have been reported in studies of vaccination with wild-type adenovirus (Couch *et al.*, 1963; Top *et al.*, 1971), demonstrating their safety and therapeutic potential as *in vivo* gene transfer vectors.

[00116] Knowledge of the genetic organization of adenovirus, a 36 kb, linear,  
10 double-stranded DNA virus, allows substitution of large pieces of adenoviral DNA with foreign sequences up to 7 kb (Grunhaus and Horwitz, 1992). In contrast to retrovirus, the adenoviral infection of host cells does not result in chromosomal integration because adenoviral DNA can replicate in an episomal manner without potential genotoxicity. Also, adenoviruses are structurally stable, and no genome rearrangement has been detected after extensive  
15 amplification.

[00117] Adenovirus may be used as a gene transfer vector because of its mid-sized genome, ease of manipulation, high titer, wide target-cell range and high infectivity. Both ends of the viral genome contain 100-200 base pair inverted repeats (ITRs), which are cis elements necessary for viral DNA replication and packaging. The early (E) and late (L) regions of the  
20 genome contain different transcription units that are divided by the onset of viral DNA replication. The E1 region (E1A and E1B) encodes proteins responsible for the regulation of transcription of the viral genome and a few cellular genes. The expression of the E2 region (E2A and E2B) results in the synthesis of the proteins for viral DNA replication. These proteins are involved in DNA replication, late gene expression and host cell shut-off (Renan, 1990).  
25 The products of the late genes, including the majority of the viral capsid proteins, are expressed only after significant processing of a single primary transcript issued by the major late promoter (MLP). The MLP, (located at 16.8 m.u.) is particularly efficient during the late phase of infection, and all the mRNAs issued from this promoter possess a 5'-tripartite leader (TPL) sequence which makes them particular mRNA's for translation.

[00118] A recombinant adenovirus provided herein can be generated from  
30 homologous recombination between a shuttle vector and provirus vector. Due to the possible recombination between two proviral vectors, wild-type adenovirus may be generated from this

process. Therefore, a single clone of virus is isolated from an individual plaque and its genomic structure is examined.

[00119] The adenovirus vector may be replication defective, or at least conditionally defective, the nature of the adenovirus vector is not believed to be crucial to the successful practice of the present disclosure. The adenovirus may be of any of the 42 different known serotypes or subgroups A-F. Adenovirus type 5 of subgroup C is the particular starting material in order to obtain the conditional replication-defective adenovirus vector for use in the present disclosure. This is because Adenovirus type 5 is a human adenovirus about which a great deal of biochemical and genetic information is known, and it has historically been used for most constructions employing adenovirus as a vector.

[00120] Nucleic acids can be introduced to adenoviral vectors as a position from which a coding sequence has been removed. For example, a replication defective adenoviral vector can have the E1-coding sequences removed. The polynucleotide encoding the gene of interest may also be inserted in lieu of the deleted E3 region in E3 replacement vectors as described by Karlsson *et al.* (1986) or in the E4 region where a helper cell line or helper virus complements the E4 defect.

[00121] Generation and propagation of replication deficient adenovirus vectors can be performed with helper cell lines. One unique helper cell line, designated 293, was transformed from human embryonic kidney cells by Ad5 DNA fragments and constitutively expresses E1 proteins (Graham *et al.*, 1977). Since the E3 region is dispensable from the adenovirus genome (Jones and Shenk, 1978), adenovirus vectors, with the help of 293 cells, carry foreign DNA in either the E1, the E3, or both regions (Graham and Prevec, 1991).

[00122] Helper cell lines may be derived from human cells such as human embryonic kidney cells, muscle cells, hematopoietic cells or other human embryonic mesenchymal or epithelial cells. Alternatively, the helper cells may be derived from the cells of other mammalian species that are permissive for human adenovirus. Such cells include, *e.g.*, Vero cells or other monkey embryonic mesenchymal or epithelial cells. As stated above, a particular helper cell line is 293.

[00123] Methods for producing recombinant adenovirus are known in the art, such as U.S. Patent No. 6740320, incorporated herein by reference. Also, Racher *et al.* (1995) have disclosed improved methods for culturing 293 cells and propagating adenovirus. In one format,

natural cell aggregates are grown by inoculating individual cells into 1 liter siliconized spinner flasks (Techne, Cambridge, UK) containing 100-200 ml of medium. Following stirring at 40 rpm, the cell viability is estimated with trypan blue. In another format, Fibra-Cel microcarriers (Bibby Sterlin, Stone, UK) (5 g/l) are employed as follows. A cell inoculum, resuspended in 5 ml of medium, is added to the carrier (50 ml) in a 250 ml Erlenmeyer flask and left stationary, with occasional agitation, for 1 to 4 hours. The medium is then replaced with 50 ml of fresh medium and shaking initiated. For virus production, cells are allowed to grow to about 80% confluence, after which time the medium is replaced (to 25% of the final volume) and adenovirus added at an MOI of 0.05. Cultures are left stationary overnight, following which the volume is increased to 100% and shaking commenced for another 72 hours.

iv. **Adeno-associated Viral Vector**

**[00124]** Adeno-associated virus (AAV) is may be used in the present disclosure as it has a high frequency of integration and it can infect nondividing cells, thus making it useful for delivery of genes into mammalian cells (Muzyczka, 1992). AAV has a broad host range for infectivity (Tratschin, *et al.*, 1984; Laughlin, *et al.*, 1986; Lebkowski, *et al.*, 1988; McLaughlin, *et al.*, 1988), which means it is applicable for use with the present disclosure. Details concerning the generation and use of rAAV vectors are described in U.S. Patent No. 5,139,941 and U.S. Patent No. 4,797,368.

**[00125]** AAV is a dependent parvovirus in that it requires coinfection with another virus (*e.g.*, adenovirus or a member of the herpes virus family) to undergo a productive infection in cultured cells (Muzyczka, 1992). In the absence of coinfection with helper virus, the wild-type AAV genome integrates through its ends into human chromosome 19 where it resides in a latent state as a provirus (Kotin *et al.*, 1990; Samulski *et al.*, 1991). rAAV, however, is not restricted to chromosome 19 for integration unless the AAV Rep protein is also expressed (Shelling and Smith, 1994). When a cell carrying an AAV provirus is superinfected with a helper virus, the AAV genome is rescued from the chromosome or from a recombinant plasmid, and a normal productive infection is established (Samulski *et al.*, 1989; McLaughlin *et al.*, 1988; Kotin *et al.*, 1990; Muzyczka, 1992).

**[00126]** A recombinant AAV (rAAV) virus may be made by cotransfecting a plasmid containing the gene of interest flanked by the two AAV terminal repeats (McLaughlin *et al.*, 1988; Samulski *et al.*, 1989; each incorporated herein by reference) and an expression plasmid containing the wild-type AAV coding sequences without the terminal repeats, for

example pIM45 (McCarty *et al.*, 1991). The cells can also be infected or transfected with adenovirus or plasmids carrying the adenovirus genes required for AAV helper function. rAAV virus stocks made in such fashion are contaminated with adenovirus which must be physically separated from the rAAV particles (for example, by cesium chloride density centrifugation).  
5 Alternatively, adenovirus vectors containing the AAV coding regions or cell lines containing the AAV coding regions and some or all of the adenovirus helper genes could be used (Yang *et al.*, 1994; Clark *et al.*, 1995). Cell lines carrying the rAAV DNA as an integrated provirus can also be used (Flotte *et al.*, 1995).

#### v. Other Viral Vectors

10 [00127] Other viral vectors may be employed as constructs in the present disclosure. Vectors derived from viruses such as vaccinia virus (Ridgeway, 1988; Baichwal and Sugden, 1986; Coupar *et al.*, 1988) and herpes simplex viruses may be employed. They offer several attractive features for various mammalian cells (Friedmann, 1989; Ridgeway, 1988; Baichwal and Sugden, 1986; Coupar *et al.*, 1988; Horwich *et al.*, 1990). In some  
15 embodiments, the polynucleotide may be delivered using integrating adenovectors.

[00128] A molecularly cloned strain of Venezuelan equine encephalitis (VEE) virus has been genetically refined as a replication competent vaccine vector for the expression of heterologous viral proteins (Davis *et al.*, 1996). Studies have demonstrated that VEE infection stimulates potent CTL responses and has been suggested that VEE may be an  
20 extremely useful vector for immunizations (Caley *et al.*, 1997).

[00129] In further embodiments, the polynucleotide is housed within an infective virus that has been engineered to express a specific binding ligand. The virus particle will thus bind specifically to the cognate receptors of the target cell and deliver the contents to the cell. Specific targeting of retrovirus vectors may be based on the chemical modification of a  
25 retrovirus by the chemical addition of lactose residues to the viral envelope. This modification can permit the specific infection of hepatocytes via sialoglycoprotein receptors.

[00130] For example, targeting of recombinant retroviruses was designed in which biotinylated antibodies against a retroviral envelope protein and against a specific cell receptor were used. The antibodies were coupled via the biotin components by using  
30 streptavidin (Roux *et al.*, 1989). Using antibodies against major histocompatibility complex

class I and class II antigens, they demonstrated the infection of a variety of human cells that bore those surface antigens with an ecotropic virus *in vitro* (Roux *et al.*, 1989).

## 2. Other Methods of Nucleic Acid Delivery

[00131] In addition to viral delivery of the polynucleotides comprising a cell  
5 cycle-dependent promoter operatively linked to a suicide gene, the following are additional  
methods of recombinant gene delivery to a given host cell and are thus considered in the present  
disclosure.

[00132] Introduction of a nucleic acid, such as DNA or RNA, may use any  
suitable methods for nucleic acid delivery for transformation of a cell, as described herein or  
10 as would be known to one of ordinary skill in the art. Such methods include, but are not limited  
to, direct delivery of DNA such as by injection of naked DNA, nanoparticles, such as lipid  
nanoparticles, gene gun, *ex vivo* transfection (Wilson *et al.*, 1989, Nabel *et al.*, 1989), by  
injection (U.S. Patent Nos. 5,994,624, 5,981,274, 5,945,100, 5,780,448, 5,736,524, 5,702,932,  
5,656,610, 5,589,466 and 5,580,859, each incorporated herein by reference), including  
15 microinjection (Harland and Weintraub, 1985; U.S. Patent No. 5,789,215, incorporated herein  
by reference); by electroporation (U.S. Patent No. 5,384,253, incorporated herein by reference;  
Tur-Kaspa *et al.*, 1986; Potter *et al.*, 1984); by calcium phosphate precipitation (Graham and  
Van Der Eb, 1973; Chen and Okayama, 1987; Rippe *et al.*, 1990); by using DEAE-dextran  
followed by polyethylene glycol (Gopal, 1985); by direct sonic loading (Fechheimer *et al.*,  
20 1987); by liposome mediated transfection (Nicolau and Sene, 1982; Fraley *et al.*, 1979;  
Nicolau *et al.*, 1987; Wong *et al.*, 1980; Kaneda *et al.*, 1989; Kato *et al.*, 1991) and receptor-  
mediated transfection (Wu and Wu, 1987; Wu and Wu, 1988); by microprojectile  
bombardment (PCT Application Nos. WO 94/09699 and 95/06128; U.S. Patent Nos.  
5,610,042; 5,322,783 5,563,055, 5,550,318, 5,538,877 and 5,538,880, and each incorporated  
25 herein by reference); by agitation with silicon carbide fibers (Kaeppler *et al.*, 1990; U.S. Patent  
Nos. 5,302,523 and 5,464,765, each incorporated herein by reference); by  
*Agrobacterium*-mediated transformation (U.S. Patent Nos. 5,591,616 and 5,563,055, each  
incorporated herein by reference); by desiccation/inhibition-mediated DNA uptake (Potrykus  
*et al.*, 1985), and any combination of such methods. Through the application of techniques  
30 such as these, organelle(s), cell(s), tissue(s) or organism(s) may be stably or transiently  
transformed.

i. Electroporation

[00133] In certain particular embodiments of the present disclosure, the gene construct is introduced into target cells via electroporation. Electroporation involves the exposure of cells (or tissues) and DNA (or a DNA complex) to a high-voltage electric discharge.

[00134] It is contemplated that electroporation conditions for hyperproliferative cells from different sources may be optimized. One may particularly wish to optimize such parameters as the voltage, the capacitance, the time and the electroporation media composition. The execution of other routine adjustments will be known to those of skill in the art. See *e.g.*, Hoffman, 1999; Heller *et al.*, 1996.

ii. Lipid-Mediated Transformation

[00135] In a further embodiment, the polynucleotide comprising a cell cycle-dependent promoter operatively linked to a suicide gene may be entrapped in a liposome or lipid formulation. Liposomes are vesicular structures characterized by a phospholipid bilayer membrane and an inner aqueous medium. Multilamellar liposomes have multiple lipid layers separated by aqueous medium. They form spontaneously when phospholipids are suspended in an excess of aqueous solution. The lipid components undergo self-rearrangement before the formation of closed structures and entrap water and dissolved solutes between the lipid bilayers (Ghosh and Bachhawat, 1991). Also contemplated is a gene construct complexed with Lipofectamine (Gibco BRL).

[00136] Lipid-mediated nucleic acid delivery and expression of foreign DNA *in vitro* has been very successful (Nicolau and Sene, 1982; Fraley *et al.*, 1979; Nicolau *et al.*, 1987). Wong *et al.* (1980) demonstrated the feasibility of lipid-mediated delivery and expression of foreign DNA in cultured chick embryo, HeLa and hepatoma cells.

[00137] Lipid based non-viral formulations provide an alternative to adenoviral gene therapies. Although many cell culture studies have documented lipid based non-viral gene transfer, systemic gene delivery via lipid based formulations has been limited. A major limitation of non-viral lipid based gene delivery is the toxicity of the cationic lipids that comprise the non-viral delivery vehicle. The *in vivo* toxicity of liposomes partially explains the discrepancy between *in vitro* and *in vivo* gene transfer results. Another factor contributing to this contradictory data is the difference in lipid vehicle stability in the presence and absence of



serum proteins. The interaction between lipid vehicles and serum proteins has a dramatic impact on the stability characteristics of lipid vehicles (Yang and Huang, 1997). Cationic lipids attract and bind negatively charged serum proteins. Lipid vehicles associated with serum proteins are either dissolved or taken up by macrophages leading to their removal from circulation. Current *in vivo* lipid delivery methods use subcutaneous, intradermal, intratumoral, or intracranial injection to avoid the toxicity and stability problems associated with cationic lipids in the circulation. The interaction of lipid vehicles and plasma proteins is responsible for the disparity between the efficiency of *in vitro* (Felgner *et al.*, 1987) and *in vivo* gene transfer (Zhu *et al.*, 1993; Philip *et al.*, 1993; Solodin *et al.*, 1995; Liu *et al.*, 1995; Thierry *et al.*, 1995; Tsukamoto *et al.*, 1995; Aksentijevich *et al.*, 1996).

**[00138]** Advances in lipid formulations have improved the efficiency of gene transfer *in vivo* (Templeton *et al.* 1997; WO 98/07408). A novel lipid formulation composed of an equimolar ratio of 1,2-bis(oleoyloxy)-3-(trimethyl ammonio)propane (DOTAP) and cholesterol significantly enhances systemic *in vivo* gene transfer, approximately 150 fold. The DOTAP:cholesterol lipid formulation forms unique structure termed a "sandwich liposome". This formulation is reported to "sandwich" DNA between an invaginated bi-layer or 'vase' structure. Beneficial characteristics of these lipid structures include a positive  $\rho$ , colloidal stabilization by cholesterol, two dimensional DNA packing and increased serum stability. Patent Application Nos. 60/135,818 and 60/133,116 discuss formulations that may be used with the present disclosure.

**[00139]** The production of lipid formulations often is accomplished by sonication or serial extrusion of liposomal mixtures after (I) reverse phase evaporation (II) dehydration-rehydration (III) detergent dialysis and (IV) thin film hydration. Once manufactured, lipid structures can be used to encapsulate compounds that are toxic (chemotherapeutics) or labile (nucleic acids) when in circulation. Lipid encapsulation has resulted in a lower toxicity and a longer serum half-life for such compounds (Gabizon *et al.*, 1990). Numerous disease treatments are using lipid based gene transfer strategies to enhance conventional or establish novel therapies, in particular therapies for treating hyperproliferative diseases.

### 30 iii. **Cell-Permeating Peptides**

**[00140]** The present disclosure contemplates fusing or conjugating a cell-penetrating peptide (also called a cell delivery domain, or cell transduction domain) to the

polynucleotide comprising a cell cycle-dependent promoter operatively linked to a suicide gene. Such domains are well known in the art and are generally characterized as short amphipathic or cationic peptides and peptide derivatives, often containing multiple lysine and arginine residues (Fischer, 2007). Of particular interest are the TAT sequence from HIV1, and poly-D-Arg and poly-D-Lys sequences (*e.g.*, dextrorotary residues, eight residues in length).

## B. Regulatory Elements

[00141] Expression cassettes included in vectors useful in the present disclosure in particular contain (in a 5'-to-3' direction) a eukaryotic transcriptional promoter operably linked to a protein-coding sequence, splice signals including intervening sequences, and a transcriptional termination/polyadenylation sequence. The promoters and enhancers that control the transcription of protein encoding genes in eukaryotic cells are composed of multiple genetic elements. The cellular machinery is able to gather and integrate the regulatory information conveyed by each element, allowing different genes to evolve distinct, often complex patterns of transcriptional regulation. A promoter used in the context of the present disclosure includes a cell-cycle dependent promoter.

### 1. Promoter/Enhancers

[00142] In certain embodiments, the expression constructs provided herein comprise a cell-cycle dependent promoter to drive expression of the suicide gene. A promoter generally comprises a sequence that functions to position the start site for RNA synthesis. The best known example of this is the TATA box, but in some promoters lacking a TATA box, such as, for example, the promoter for the mammalian terminal deoxynucleotidyl transferase gene and the promoter for the SV40 late genes, a discrete element overlying the start site itself helps to fix the place of initiation. Additional promoter elements regulate the frequency of transcriptional initiation. Typically, these are located in the region 30-110 bp upstream of the start site, although a number of promoters have been shown to contain functional elements downstream of the start site as well. To bring a coding sequence "under the control of" a promoter, one positions the 5' end of the transcription initiation site of the transcriptional reading frame "downstream" of (*i.e.*, 3' of) the chosen promoter. The "upstream" promoter stimulates transcription of the DNA and promotes expression of the encoded RNA.

[00143] The spacing between promoter elements frequently is flexible, so that promoter function is preserved when elements are inverted or moved relative to one another.

In the tk promoter, the spacing between promoter elements can be increased to 50 bp apart before activity begins to decline. Depending on the promoter, it appears that individual elements can function either cooperatively or independently to activate transcription. A promoter may or may not be used in conjunction with an “enhancer,” which refers to a cis-acting regulatory sequence involved in the transcriptional activation of a nucleic acid sequence.

**[00144]** A promoter may be one naturally associated with a nucleic acid sequence, as may be obtained by isolating the 5' non-coding sequences located upstream of the coding segment and/or exon. Such a promoter can be referred to as “endogenous.” Similarly, an enhancer may be one naturally associated with a nucleic acid sequence, located either downstream or upstream of that sequence. Alternatively, certain advantages will be gained by positioning the coding nucleic acid segment under the control of a recombinant or heterologous promoter, which refers to a promoter that is not normally associated with a nucleic acid sequence in its natural environment. A recombinant or heterologous enhancer refers also to an enhancer not normally associated with a nucleic acid sequence in its natural environment. Such promoters or enhancers may include promoters or enhancers of other genes, and promoters or enhancers isolated from any other virus, or prokaryotic or eukaryotic cell, and promoters or enhancers not “naturally occurring,” *i.e.*, containing different elements of different transcriptional regulatory regions, and/or mutations that alter expression. For example, promoters that are most commonly used in recombinant DNA construction include the  $\beta$ -lactamase (penicillinase), lactose and tryptophan (trp) promoter systems. In addition to producing nucleic acid sequences of promoters and enhancers synthetically, sequences may be produced using recombinant cloning and/or nucleic acid amplification technology, including PCR<sup>TM</sup>, in connection with the compositions disclosed herein (*see* U.S. Patent Nos. 4,683,202 and 5,928,906, each incorporated herein by reference). Furthermore, it is contemplated that the control sequences that direct transcription and/or expression of sequences within non-nuclear organelles such as mitochondria, chloroplasts, and the like, can be employed as well.

**[00145]** Naturally, it will be important to employ a promoter and/or enhancer that effectively directs the expression of the DNA segment in the organelle, cell type, tissue, organ, or organism chosen for expression. Those of skill in the art of molecular biology generally know the use of promoters, enhancers, and cell type combinations for protein expression, (*see*, for example Sambrook *et al.* 1989, incorporated herein by reference). The promoters employed may be constitutive, tissue-specific, inducible, and/or useful under the appropriate conditions

to direct high level expression of the introduced DNA segment, such as is advantageous in the large-scale production of recombinant proteins and/or peptides. The promoter may be heterologous or endogenous.

**[00146]** Additionally any promoter/enhancer combination (as per, for example, the Eukaryotic Promoter Data Base EPDB, through world wide web at epd.isb-sib.ch/) could also be used to drive expression. Use of a T3, T7 or SP6 cytoplasmic expression system is another possible embodiment. Eukaryotic cells can support cytoplasmic transcription from certain bacterial promoters if the appropriate bacterial polymerase is provided, either as part of the delivery complex or as an additional genetic expression construct.

**[00147]** For cell replacement therapy using precursor cells, it is preferable that the gene is expressed under the control of a cell cycle-dependent promoter. Examples of cell cycle-dependent promoters include, but are not limited to those listed in Table 1. Cell cycle-dependent promoters may be derived from genes involved in the cell cycle, such as genes with expression in the G(2) phase and mitosis. Cell cycle-dependent promoters may comprise synthetic promoters. For cell replacement therapy, progenitors should generally maintain migratory potential and integrate appropriately into degenerating regions.

**[00148]** Table 1: Cell cycle-dependent promoters.

Promoter	References
Ki-67	Zambon A.C. <i>Cytometry A</i> . 77(6):564-570, 2010.
PCNA	Whitfield <i>et al.</i> , <i>Nature Reviews Cancer</i> 6:99-106, 2006.
CKS2	
TOP2A	
BUB1, BUB1B	
CHEK1	
AURKA, AURKB	
TRIP, TRIP13	
CDC7	

ORC1L	
PRIM1	
RFC1	
RRM1, RRM2	
FEN1	
CCNA2, CCNB1, CCNE1, CCNF	
CDC20	
DDX11	
E2F3	
PKMYT1	
PLK1	
TIMP1	
CDC25C	
CENPF, CENPN	
MCM2, MCM3, MCM4, MCM5, MCM6, MCM7, MCM10	
E2F	Dimova <i>et al.</i> , <i>Oncogene</i> 24:2810-2826, 2005.
SKP2	Imaki <i>et al.</i> , <i>Cancer Res.</i> 63(15):4607-13, 2003.
CHR	Muller <i>et al.</i> , <i>Nucleic Acids Res.</i> 40(4):1561- 1578, 2012.
SMC4	Ren <i>et al.</i> , <i>Genes and Dev.</i> 16:245-256, 2002.
MELK	Fischer <i>et al.</i> , <i>Nucleic Acids Research</i> 2015.
CKAP2	Kang <i>et al.</i> , <i>Biochem Biophys Res Commun.</i> 420(4):822-7, 2012.
DBF4	Wu X. and Lee H. <i>Oncogene</i> 21(51): 7786-96, 2002.
CDK4	Pawar <i>et al.</i> <i>Oncogene</i> 23(36):6125-35, 2004.

ZWILCH	Salvatore <i>et al.</i> , <i>Cancer Res.</i> 67(21):10148-10158, 2007.
POLE2	
ZWINT	
GINS2	
SMC4	
HMMR	
NCAPH	
TTK	
PBK	
CEP55	
ECT2	Seguin <i>et al.</i> , <i>Molecular and Cellular Biology</i> 29(2), 2009.
STIL	
FBXO5	Balciunaite <i>et al.</i> , <i>Molecular and Cellular Biology</i> 25(18), 2005.
SHCBP1	Grant <i>et al.</i> , <i>Molecular Biology of the Cell</i> 24(23):3634-3650, 2013.
KIF23, KIF11, KIF4A	
DLGAP5	
RRM2	Zhang <i>et al.</i> , <i>Molecular Cancer</i> 8(11), 2009.
CDCA7	Gill <i>et al.</i> , <i>Molecular and Cellular Biology</i> 33(3):498-513, 2013.
HELLS	Mjelle <i>et al.</i> , <i>DNA Repair</i> 30:53-67, 2015.
SGOL2	Llano <i>et al.</i> , <i>Genes Dev.</i> 22(17):2400-13, 2008.
KIAA0101/p15 <sup>PAF</sup>	Chang <i>et al.</i> , <i>PLOS One</i> 8(4):e61196, 2013.
NUF2	Suzuki <i>et al.</i> , <i>Nature Cell Biology</i> 18:382-392, 2016.
NDC80	
NUSAP1	Yamamoto <i>et al.</i> , <i>Nucleic Acid Res.</i> 2016.

DTL	Westendorp <i>et al.</i> , <i>Nucleic Acids Research</i> 1-13, 2011.
MLF1IP	
ASPM	Wu <i>et al.</i> , <i>J Biol Chem.</i> 3(43):29396-29404, 2008.

[00149] In certain aspects, methods of the disclosure also concern enhancer sequences, *i.e.*, nucleic acid sequences that increase a promoter's activity and that have the potential to act in cis, and regardless of their orientation, even over relatively long distances (up to several kilobases away from the target promoter). However, enhancer function is not necessarily restricted to such long distances as they may also function in close proximity to a given promoter.

## 2. Initiation Signals and Linked Expression

[00150] A specific initiation signal also may be used in the expression constructs provided in the present disclosure for efficient translation of coding sequences. These signals include the ATG initiation codon or adjacent sequences. Exogenous translational control signals, including the ATG initiation codon, may need to be provided. One of ordinary skill in the art would readily be capable of determining this and providing the necessary signals. It is well known that the initiation codon must be "in-frame" with the reading frame of the desired coding sequence to ensure translation of the entire insert. The exogenous translational control signals and initiation codons can be either natural or synthetic. The efficiency of expression may be enhanced by the inclusion of appropriate transcription enhancer elements.

[00151] In certain embodiments, the use of internal ribosome entry sites (IRES) elements are used to create multigene, or polycistronic, messages. IRES elements are able to bypass the ribosome scanning model of 5' methylated Cap dependent translation and begin translation at internal sites (Pelletier and Sonenberg, 1988). IRES elements from two members of the picornavirus family (polio and encephalomyocarditis) have been described (Pelletier and Sonenberg, 1988), as well an IRES from a mammalian message (Macejak and Sarnow, 1991). IRES elements can be linked to heterologous open reading frames. Multiple open reading frames can be transcribed together, each separated by an IRES, creating polycistronic messages. By virtue of the IRES element, each open reading frame is accessible to ribosomes for efficient translation. Multiple genes can be efficiently expressed using a single promoter/enhancer to transcribe a single message (see U.S. Patent Nos. 5,925,565 and 5,935,819, each herein incorporated by reference).

[00152] Additionally, certain 2A sequence elements could be used to create linked- or co-expression of genes in the constructs provided in the present disclosure. For example, cleavage sequences could be used to co-express genes by linking open reading frames to form a single cistron. An exemplary cleavage sequence is the F2A (Foot-and-mouth disease virus 2A) or a “2A-like” sequence (*e.g.*, *Thosea asigna* virus 2A; T2A) (Minskaia and Ryan, 2013).

### 3. Origins of Replication

[00153] In order to propagate a vector in a host cell, it may contain one or more origins of replication sites (often termed “ori”), for example, a nucleic acid sequence corresponding to oriP of EBV as described above or a genetically engineered oriP with a similar or elevated function in programming, which is a specific nucleic acid sequence at which replication is initiated. Alternatively a replication origin of other extra-chromosomally replicating virus as described above or an autonomously replicating sequence (ARS) can be employed.

### 4. Selection and Screenable Markers

[00154] In some embodiments, cells containing a construct of the present disclosure may be identified *in vitro* or *in vivo* by including a marker in the expression vector. Such markers would confer an identifiable change to the cell permitting easy identification of cells containing the expression vector. Generally, a selection marker is one that confers a property that allows for selection. A positive selection marker is one in which the presence of the marker allows for its selection, while a negative selection marker is one in which its presence prevents its selection. An example of a positive selection marker is a drug resistance marker.

[00155] Usually the inclusion of a drug selection marker aids in the cloning and identification of transformants, for example, genes that confer resistance to neomycin, puromycin, hygromycin, DHFR, GPT, zeocin and histidinol are useful selection markers. In addition to markers conferring a phenotype that allows for the discrimination of transformants based on the implementation of conditions, other types of markers including screenable markers such as GFP, whose basis is colorimetric analysis, are also contemplated. Alternatively, screenable enzymes as negative selection markers such as herpes simplex virus thymidine kinase (*tk*) or chloramphenicol acetyltransferase (CAT) may be utilized. One of skill in the art would also know how to employ immunologic markers, possibly in conjunction with FACS analysis. The marker used is not believed to be important, so long as it is capable



of being expressed simultaneously with the nucleic acid encoding a gene product. Further examples of selection and screenable markers are well known to one of skill in the art.

### C. Suicide Genes and Prodrugs

[00156] In some embodiments, a suicide gene is a nucleic acid which, upon  
5 administration of a prodrug, effects transition of a gene product to a compound which kills its host cell. Examples of suicide gene/prodrug combinations which may be used are Herpes Simplex Virus-thymidine kinase (HSV-tk) and ganciclovir, acyclovir, or FIAU; oxidoreductase and cycloheximide; cytosine deaminase and 5-fluorocytosine; thymidine kinase thymidilate kinase (Tdk::Tmk) and AZT; and deoxycytidine kinase and cytosine  
10 arabinoside. The *E.coli* purine nucleoside phosphorylase which converts the prodrug 6-methylpurine deoxyriboside to toxic purine 6-methylpurine may also be used.

[00157] In some embodiments, the HSV thymidine kinase (TK) suicide gene may have one or more mutations from the wild-type or unmutated HSV TK. As utilized herein, it should be understood that “unmutated thymidine kinase” refers to native or wild-type  
15 thymidine kinase such as that described by McKnight *et al.* (*Nucl. Acids Res.* 8:5949-5964, 1980). The TK mutants can have one or more amino acid substitutions at residues 159-161 and 168-169 of HSV TK (Black *et al.*, *Proc. Nat'l Acad. USA* 93:3525-3529, 1996). The TK mutant used in the present methods may be SR11, SR26, SR39, SR4, SR15, SR32, or SR53 TK mutants. For example, the HSV TK can be HSV1-SR39TK (*i.e.*, <sup>159</sup>IFL<sub>161</sub> and <sup>168</sup>FM<sub>169</sub>; amino  
20 acid substitution at position 159 is leucine to isoleucine, at position 160 is isoleucine to phenylalanine, at position 161 is phenylalanine to leucine, at position 168 is alanine to phenylalanine, and at position 169 is leucine to methionine) which has an enhanced ability to convert the prodrug acyclovir and/or ganciclovir into cytotoxic agents (U.S. Patent Publication Nos. 20130011903 and 20120142071; incorporated herein by reference in their entirety).

[00158] The mutations may be upstream or downstream of the DRH nucleoside  
25 binding site. For example, mutations which encode one or more amino acid substitutions from 1 to 7 amino acids upstream from the DRH nucleoside binding site are contemplated. The biological activity of such kinases may be readily determined utilizing any of the assays which are described herein, including for example, determination of the rate of nucleoside analogue  
30 uptake, determination of the rate of nucleoside or nucleoside analogue phosphorylation. In addition, thymidine kinase mutants may be readily selected which are characterized by other

biological properties, such as thermostability, and protein stability (*e.g.*, described in U.S. Patent No. 6,451,571).

**[00159]** Briefly, thymidine kinase mutants of the present disclosure may be prepared from a wide variety of Herpesviridae thymidine kinases, including for example both primate  
5 herpesviruses, and nonprimate herpesviruses such as avian herpesviruses. Representative examples of suitable herpesviruses include Herpes Simplex Virus Type 1 (McKnight *et al.*, *Nuc. Acids Res* 8:5949-5964, 1980), Herpes Simplex Virus Type 2 (Swain and Galloway, *J. Virol.* 46:1045-1050, 1983), Varicella Zoster Virus (Davison and Scott, *J. Gen. Virol.* 67:1759-1816, 1986), marmoset herpesvirus (Otsuka and Kit, *Virology* 135:316-330, 1984), feline  
10 herpesvirus type 1 (Nunberg *et al.*, *J. Virol.* 63:3240-3249, 1989), pseudorabies virus (Kit and Kit, U.S. Patent No. 4,514,497, 1985), equine herpesvirus type 1 (Robertson and Whalley, *Nuc. Acids Res.* 16:11303-11317, 1988), bovine herpesvirus type 1 (Mittal and Field, *J. Virol.* 70:2901-2918, 1989), turkey herpesvirus (Martin *et al.*, *J. Virol.* 63:2847-2852, 1989), Marek's disease virus (Scott *et al.*, *J. Gen. Virol.* 70:3055-3065, 1989), herpesvirus saimiri (Honest *et al.*, *J. Gen. Virol.* 70:3003-3013, 1989) and Epstein-Barr virus (Baer *et al.*, *Nature (London)* 310:207-311, 1984).

**[00160]** Such herpesviruses may be readily obtained from commercial sources such as the American Type Culture Collection ("ATCC", Rockville, Md.). Deposits of certain of the above-identified herpesviruses may be readily obtained from the ATCC, for example: ATCC  
20 No. VR-539 (Herpes simplex type 1); ATCC Nos. VR-734 and VR-540 (Herpes Simplex type 2); ATCC No. VR-586 (Varicella Zoster Virus); ATCC No. VR-783 (Infectious laryngotracheitis); ATCC Nos. VR-624 VR-987, VR-2103, VR-2001, VR-2002, VR-2175, VR-585 (Marek's disease virus); ATCC Nos. VR-584B and VR-584B (turkey herpesvirus); ATCC Nos. VR-631 and VR-842 (bovine herpesvirus type 1); and ATCC Nos. VR-2003, VR-25 2229 and VR-700 (equine herpesvirus type 1). Herpesviruses may also be readily isolated and identified from naturally occurring sources (*e.g.*, from an infected animal).

**[00161]** Thymidine kinase mutants used in the present disclosure may be constructed using a wide variety of techniques. For example, mutations may be introduced at particular loci by synthesizing oligonucleotides containing a mutant sequence, flanked by restriction sites  
30 enabling ligation to fragments of the native sequence. Following ligation, the resulting reconstructed sequence encodes a derivative having the desired amino acid insertion, substitution, or deletion.

**[00162]** Alternatively, oligonucleotide-directed site-specific (or segment specific) mutagenesis procedures may be employed to provide an altered gene having particular codons altered according to the substitution, deletion, or insertion required. Deletion or truncation derivatives of thymidine kinase mutants may also be constructed by utilizing convenient restriction endonuclease sites adjacent to the desired deletion. Subsequent to restriction, overhangs may be filled in, and the DNA religated. Exemplary methods of making the alterations set forth above are disclosed by Sambrook *et al.* (*Molecular cloning: A Laboratory Manual*, 2d Ed., Cold Spring Harbor Laboratory Press, 1989).

**[00163]** Thymidine kinase mutants may also be constructed utilizing techniques of PCR mutagenesis, chemical mutagenesis (Drinkwater and Klinedinst, *PNAS* 83:3402-3406, 1986), by forced nucleotide misincorporation (*e.g.*, Liao and Wise *Gene* 88:107-111, 1990), or by use of randomly mutagenized oligonucleotides (Horwitz *et al.*, *Genome* 3:112-117, 1989).

**[00164]** Table 2: Suicide Genes and Prodrugs (Denny *et al.*, *Biomedicine Biotechnol.* 1:48-70, 2003).

Suicide Gene	Prodrug
HSV thymidine kinase (TK)	Ganciclovir (GCV) Ganciclovir elaidic acid ester Penciclovir (PCV) Acyclovir (ACV) Valacyclovir (VCV) (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) Zidovuline (AZT) 2'-exo-methanocarbothymidine (MCT)
Cytosine Deaminase (CD)	5-fluorocytosine (5-FC)
Purine nucleoside phosphorylase (PNP)	6-methylpurine deoxyriboside (MEP) fludarabine (FAMP)
Cytochrome p450 enzymes (CYP)	Cyclophosphamide (CPA) Ifosfamide (IFO) 4-ipomeanol (4-IM)

Carboxypeptidases (CP)	4-[(2-chloroethyl)(2-mesyloxyethyl)amino]benzoyl-L-glutamic acid (CMDA)  Hydroxy- and amino-aniline mustards  Anthracycline glutamates  Methotrexate $\alpha$ -peptides (MTX-Phe)
Caspase-9	AP1903 (Di Stasi <i>et al.</i> , 2011)
Carboxylesterase (CE)	Irinotecan (IRT)  Anthracycline acetals
Nitroreductase (NTR)	dinitroaziridinylbenzamide CB1954  dinitrobenzamide mustard SN23862  4-Nitrobenzyl carbamates  Quinones
Horse radish peroxidase (HRP)	Indole-3-acetic acid (IAA)  5-Fluoroindole-3-acetic acid (FIAA)
Guanine Ribosyltransferase (XGRTP)	6-Thioxanthine (6-TX)
Glycosidase enzymes	HM1826  Anthracycline acetals
Methionine- $\alpha,\gamma$ -lyase (MET)	Selenomethionine (SeMET)
Thymidine phosphorylase (TP)	5'-Deoxy-5-fluorouridine (5'-DFU)

#### IV. Methods of Use

[00165] PSCs to which genes have been introduced by vectors of the present disclosure (*e.g.*, pseudotyped lentiviral vectors), and cells, tissues, organs and such differentiated from these PSCs are useful for assaying and screening for various types of pharmaceutical agents. Through gene transfer into PSCs, for example, pharmaceutical agents or genes for carrying out specific differentiation of tissues or cells, and particularly preferably tissues or cells derived from primates, can be evaluated for their effects or screened for.

[00166] The present disclosure also encompasses PSCs into which vectors of the present disclosure (*e.g.*, pseudotyped lentiviral vectors) have been introduced, and differentiated cells and tissues that have differentiated from the PSCs. The differentiated cells and tissues can be identified based on marker expression and morphological characteristics  
5 specific to the tissues or cells.

#### A. Methods of Treatment

[00167] In some embodiments, the present disclosure provides methods of treating a disease or disorder in a subject comprising administering a population of precursor cells which comprise a suicide gene under the control of a cell cycle-dependent promoter. The  
10 precursor cells may be used to replace cells which are essentially non-dividing cells and any remaining cycling or proliferating cells may be eliminated by the administration of a pro-drug which is selectively kills these cycling cells. Thus, the method can prevent the formation of teratomas or tumors from the remaining cycling cells.

[00168] The treatment methods may be applied to any disease or disorder which may  
15 benefit from the replacement of a certain cell population. For example, neuronal diseases may be treated by the administration of precursor cells. Disease which affect the vasculature, such as tumor angiogenesis, may be treated by the administration of endothelial precursor cells. Cardiomyocyte precursor cells may be used in the treatment of heart diseases and pancreatic precursor cells may be used for the treatment of pancreatic diseases. Other precursor cell  
20 therapies of the present disclosure may comprise, but are not limited to, kidney precursor cells, oligodendrocyte precursor cells, hematopoietic precursor cells, myeloid precursor cells, mesenchymal precursor cells, retinal precursor cells, and osteoclast precursor cells.

[00169] In humans, there are numerous diseases affecting the CNS, many of which result in cerebellar degeneration with concomitant symptoms, such as dysmetria, ataxia, past  
25 pointing, dysdiadochokinesia, dysarthria, intention and action tremor, cerebellar nystagmus, rebound, hypotonia, and loss of equilibrium. These diseases may be alleviated using cell replacement therapy according to the specific embodiment disclosed herein.

[00170] Diseases of the CNS and brain in humans that are amenable to treatment using the methods of the present disclosure include a wide variety of diseases and disorders,  
30 including for example, Huntington's disease; Alzheimer's disease (both sporadic and familial); Parkinson's disease and Parkinson's disease-like symptoms, such as muscle tremors, muscle

weakness, rigidity, bradykinesia, alterations in posture and equilibrium, and dementia; amyotrophic lateral sclerosis (ALS); spinal cord injury; severe epilepsy; traumatic brain injury; and the like.

5           **[00171]**   Accordingly, the methods of the present disclosure may be used to alleviate abnormalities of the CNS and cerebellum that result in demyelination, dysmyelination, dementia, dysmetria, ataxia, past pointing, dysdiadochokinesia, dysarthria, intention and action tremor, cerebellar nystagmus, rebound, hypotonia, and loss of equilibrium. It is well established that patients with Parkinson's suffer from progressively disabled motor control due to loss of dopaminergic neurons within the basal ganglia, which innervate the striatum. Neural precursor cells can be directed toward a dopaminergic fate and delivered into the striatum using the systems described herein to prevent overgrowth and tumor formation. Likewise, neural precursors of the present disclosure can be directed toward a cholinergic fate for use in the treatment of Alzheimer's disease.

15           **[00172]**   The methods of the present disclosure also have use in the veterinary field including treatment of domestic pets and farm animals. As utilized herein, the terms "treated, prevented, or, inhibited" refer to the alteration of a disease course or progress in a statistically significant manner. Determination of whether a disease course has been altered may be readily assessed in a variety of model systems and by using standard assays, known in the art, which analyze the ability of a gene delivery vector to delay or prevent CNS or cerebellar degeneration.

20           **[00173]**   Gene delivery vectors may be delivered directly to the CNS or brain by injection into, *e.g.*, a ventricle, a cerebellar lobule and/or the striatum, using a needle, catheter or related device. In particular, within certain embodiments of the present disclosure, one or more dosages may be administered directly in the indicated manner at dosages greater than or equal to 10<sup>3</sup>, 10<sup>4</sup>, 10<sup>5</sup>, 10<sup>6</sup>, 10<sup>7</sup>, 10<sup>8</sup>, 10<sup>9</sup>, 10<sup>10</sup> or 10<sup>11</sup> cfu. Cerebellar injections are complicated by the fact that stereotaxic coordinates cannot be used to precisely target the site of an injection; there is animal to animal variation in the size of cerebellar lobules, as well as their absolute three-dimensional orientation. Thus, cholera toxin subunit b (CTb) may be used to determine the exact location of the injection and reveal the pool of transducible neurons at an injection site. Injections may fill the molecular layer, Purkinje cell layer, granule cell layer and white matter of the arbor vitae but do not extend to the deep cerebellar nuclei.

[00174] Alternatively, and preferably for treating diseases using transduced neural progenitor cells, neural progenitor cells are first transduced *ex vivo* and then delivered to the CNS. Generally, if transduced *ex vivo*, cells will be infected with the viral vectors described herein at an MOI of about 0.01 to about 50, preferably about 0.05 to about 30, and most preferably about 0.1 to about 20 MOI. For FIV vectors, an MOI of about 0.05 to about 10, preferably about 0.1 to about 5, or even 0.1 to about 1, should be sufficient. Once transfected *ex vivo*, cells can be delivered, for example, to the ventricular region, as well as to the striatum, spinal cord and neuromuscular junction, using neurosurgical techniques known in the art, and as described in the examples below, such as by stereotactic injection and injections into the eyes and ears (see, *e.g.*, Stein *et al.*, *J Virol* 73:3424-3429, 1999; Davidson *et al.*, *PNAS* 97:3428-3432, 2000; Davidson *et al.*, *Nat. Genet.* 3:219-223, 1993; and Alisky and Davidson, *Hum. Gene Ther.* 77:2315-2329, 2000). In general, the amount of transduced cells in the compositions to be delivered to the subject will be from about 10<sup>1</sup> to about 10<sup>10</sup> cells or more, more preferably about 10<sup>1</sup> to 10<sup>8</sup> cells or more, and even more preferably about 10<sup>2</sup> to about 10<sup>4</sup> cells, or more. Other effective dosages can be readily established by one of ordinary skill in the art through routine trials establishing dose response curves.

[00175] A wide variety of assays may be utilized in order to determine appropriate dosages for administration, or to assess the ability of a gene delivery vector to treat or prevent a particular disease. Certain of these assays are discussed in more detail below. For example, the ability of particular vectors to transduce cerebellar neurons and neural progenitor cells can be assessed using reporter genes, as discussed below. The ability of the transduced progenitor cells to differentiate may be tested, for example, using immunocytochemistry, as discussed below in the examples.

[00176] For systemic administration, a therapeutically effective dose can be estimated initially from *in vitro* assays. For example, a dose can be formulated in animal models to achieve a circulating concentration range that includes the IC<sub>50</sub> as determined in cell culture. Such information can be used to more accurately determine useful doses in humans. The therapy may be repeated intermittently while symptoms detectable or even when they are not detectable. The therapy may be provided alone or in combination with other drugs.

[00177] Initial dosages can also be estimated from *in vivo* data, *e.g.*, animal models, using techniques that are well known in the art. One having ordinary skill in the art could readily optimize administration to humans based on animal data.

## B. Pharmaceutical Preparations

[00178] Where clinical application of a composition containing a therapeutic cell population of the present disclosure is undertaken, it will generally be beneficial to prepare a pharmaceutical composition appropriate for the intended application. This will typically entail  
5 preparing a pharmaceutical composition that is essentially free of pyrogens, as well as any other impurities that could be harmful to humans or animals.

[00179] The phrases "pharmaceutical or pharmacologically acceptable" refers to molecular entities and compositions that do not produce an adverse, allergic or other untoward reaction when administered to an animal, such as a human, as appropriate. The preparation of  
10 a pharmaceutical composition comprising a inhibitory nucleic acid or additional active ingredient will be known to those of skill in the art in light of the present disclosure, as exemplified by Remington (2005), incorporated herein by reference. Moreover, for animal (*e.g.*, human) administration, it will be understood that preparations should meet sterility, pyrogenicity, general safety and purity standards as required by FDA Office of Biological  
15 Standards.

[00180] As used herein, "pharmaceutically acceptable carrier" includes any and all solvents, dispersion media, coatings, surfactants, antioxidants, preservatives (*e.g.*, antibacterial agents, antifungal agents), isotonic agents, absorption delaying agents, salts, preservatives, drugs, drug stabilizers, gels, binders, excipients, disintegration agents, lubricants, sweetening  
20 agents, flavoring agents, dyes, such like materials and combinations thereof, as would be known to one of ordinary skill in the art. A pharmaceutically acceptable carrier is particularly formulated for administration to a human, although in certain embodiments it may be desirable to use a pharmaceutically acceptable carrier that is formulated for administration to a non-human animal but which would not be acceptable (*e.g.*, due to governmental regulations) for  
25 administration to a human. Except insofar as any conventional carrier is incompatible with the active ingredient, its use in the therapeutic or pharmaceutical compositions is contemplated.

[00181] The present therapies of the embodiments can be administered intravenously, intradermally, intraarterially, intraperitoneally, intralesionally, intracranially, intraarticularly, intraprostatically, intrapleurally, intratracheally, intranasally, intravitreally,  
30 intravaginally, intrarectally, topically, intratumorally, intramuscularly, intraperitoneally, subcutaneously, subconjunctival, intravesicularlly, mucosally, intrapericardially, intraumbilically, intraocularly, orally, topically, locally, inhalation (*e.g.*, aerosol inhalation),



injection, infusion, continuous infusion, localized perfusion bathing target cells directly, via a catheter, via a lavage, in cremes, in lipid compositions (*e.g.*, liposomes), or by other method or any combination of the forgoing as would be known to one of ordinary skill in the art

[00182] The actual dosage amount of a composition of the present disclosure administered to a patient or subject can be determined by physical and physiological factors such as body weight, severity of condition, the type of disease being treated, previous or concurrent therapeutic interventions, idiopathy of the patient and on the route of administration. The practitioner responsible for administration will, in any event, determine the concentration of active ingredient(s) in a composition and appropriate dose(s) for the individual subject. In non-limiting examples, a dose may comprise from about 5 microgram/kg/body weight to about 500 milligram/kg/body weight, about 5 mg/kg/body weight to about 100 mg/kg/body weight, about 10 mg/kg/body weight to about 50 mg/kg/body weight, can be administered.

## V. Examples

[00183] The following examples are included to demonstrate preferred embodiments of the invention. It should be appreciated by those of skill in the art that the techniques disclosed in the examples that follow represent techniques discovered by the inventor to function well in the practice of the invention, and thus can be considered to constitute preferred modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments that are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention.

### Example 1 – Targeting of Proliferative Cells

[00184] *Generation of TK-PSC line:* The aim of this study was to develop a suicide gene approach towards the prevention of uncontrolled overgrowth of PSC-derived transplanted neural cells. For many reasons, ganciclovir and herpes simplex thymidine kinase is an attractive system for such a suicide gene technology. Indeed ganciclovir is widely used in patients and penetrates into the central nervous system. However, constitutive expression of HSV-TK would not be desirable, as this could lead to immune rejection of transplanted cells, and the use of ganciclovir could potentially lead to killing of functional transplanted neurons.

[00185] Accordingly, HSV-TK was expressed under the control of a cell cycle-dependent Ki67 promoter fragment. For this purpose the human pluripotent ESC (hPSC) line HS415 was transduced with a lentivector coding for the expression of HSV-TK under the control of the Ki67 promoter fragment (Zamboni, 2010). As the lentivector transduction efficiency of hPSC is in the range of 10-20%, a tool for selection of transduced cells was required. Thus, the construct that was used had the HSV-TK sequence fused to a zeocin resistance sequence. HSV-TK-positive cells were selected by culturing transduced hESC in the presence of zeocin (FIG. 1A). A polyclonal HSV-TK-expressing PSC line was obtained, referred to herein as TK-PSC. Neural precursor cells and mature neurons were obtained from TK-PSC and are to as TK-NPC and TK-neurons, respectively (FIG. 1B, 1C).

[00186] *Highly proliferative cells expressing Ki67/TK are sensitive to ganciclovir in vitro:* Next, TK expression was investigated in TK-PSC and in TK neurons. In TK-PSC, virtually 100% of cells expressed TK in concordance with high expression of Ki67 in these cells (FIG. 1C, upper panel). In contrast, TK neurons did not express any TK, as predicted from them being post-mitotic cells. However, there were still Ki67-positive cells in the neuronal preparation (FIG 1C, lower panel). These Ki67-positive cells likely do not reflect the presence of proliferating cells as many of the Ki67-positive cells in the neuronal preparation clearly showed a morphology of mature neurons with long neurite extension. The expression of Ki67 was also investigated, together with expression of the pluripotency markers nanog and oct3/4 by flow cytometry. In PSCs, virtually all cells were Ki67-, nanog-, and oct3/4-positive. In contrast, NPCs rapidly lost pluripotency markers after 1 week of neurosphere differentiation, while Ki67 expression decreased more slowly with levels slightly above background after 3 weeks of differentiation (FIG. 2A).

[00187] The impact of ganciclovir on TK cells was determined *in vitro* (FIG. 2B, 2C, 2D). TK PSCs were highly sensitive to ganciclovir exposure (96h) and even at ganciclovir concentrations of 2.5  $\mu$ M loss of cells was observed, which was almost complete at 10  $\mu$ M (FIG. 2B, 2C). In contrast, regular PSCs (*i.e.*, not transduced with the TK construct) were resistant to ganciclovir even at concentrations of 40  $\mu$ M (FIG. 2B, 2F). As expected from the lack of TK expression in TK neurons, TK neurons were not affected by ganciclovir concentrations up to 40  $\mu$ M, similar to the control neurons.

[00188] The time course of the ganciclovir effect was also investigated (FIG. 2D). TK PSCs were killed by Ganciclovir (40  $\mu$ M) within 4 days. TK-NPCs after 1 week of

neurosphere differentiation were still sensitive to Ganciclovir (40  $\mu$ M), however the time course of killing was markedly slowed down and complete killing was observed only after 8 days. TK-NPCs after 2 weeks of neurosphere differentiation showed only little cell growth and were not killed by ganciclovir.

5           **[00189]**   *Early, but not late ganciclovir treatment prevents tumor formation upon transplantation of highly proliferative pluripotent stem cells:* Given the encouraging results *in vitro*, it was investigated whether ganciclovir could prevent tumor formation *in vivo*. For this purpose TK-PSC were transplanted into the striatum of NOD/SCID mice. In the absence of ganciclovir, mice, sacrificed 49 days post transplantation, consistently developed teratomas  
10 (FIG. 4A), which consisted of human cells (HCM-positive) and showed abundant expression of Ki67 and Ki67 promoter-driven HSV-TK (FIG. 5Aa). There was a moderate amount of mouse microglia invasion. In contrast, mice that were treated for 15 days with ganciclovir (starting 4 days post-transplantation) had no observed teratomas (FIG. 4B). There were hardly any human cells left in the ganciclovir-treated animals, and the few surviving human cells were  
15 negative for HSV-TK and – to a large extent – also negative for Ki67, suggesting that the few surviving human cells had become post-mitotic and therefore lost sensitivity to ganciclovir (FIG. 5Ba). Thus, ganciclovir prevented teratoma formation by transplanted TK-PSC.

**[00190]**   It was next investigated whether ganciclovir could also be used to treat already established teratomas. Therefore, teratoma formation was allowed to progress for 30  
20 days (preliminary results had shown that within this time delay there was consistent teratoma formation upon transplantation of PSC) and treated with ganciclovir (or PBS) for days 30-45 post-transplantation. Mice were sacrificed 30 days after the end of the ganciclovir treatment. Under these conditions, there was teratoma formation in both, the PBS and the ganciclovir-treated animals (FIG. 6). CD31 staining showed that tumors were vascularized, suggesting that  
25 lack of perfusion did not account for the absence of a ganciclovir therapeutic effect in established tumors. Similarly, many teratoma cells showed high level expression of HSV-TK suggesting that down-regulation of the transgene was not the explanation for the lack of a therapeutic response.

**[00191]**   A previous study (Chalmers *et al.*, 2001) had suggested that alternative  
30 splicing, due to cryptic splice donor and acceptor sites, can lead to formation of an inactive TK. Another study (Kotini *et al.*, 2016) had suggested that various non-sense mutations may occur in the TK sequence in rapidly growing cells and might explain ganciclovir resistance.

Therefore, mRNA was extracted from the tumors formed upon injection of undifferentiated pluripotent cells. From these mRNA preparations, five regions of the TK protein were amplified covering a total of 1162 nucleotides, corresponding to 85% of the total TK sequence (FIG. 7A). The sequenced regions also included the proposed cryptic splice sites (e.g., amplicon 3). The PCR products were directly sequenced (FIG. 7B). The results of this sequencing determined that the all over sequence found in the tumors was identical to the plasmid HSV-TK sequence, suggesting that - if mutations had occurred - they were not representative of the majority of HSV-TK sequences within the tumor. Inspection of the sequencing results did not show any evidence for ambivalent sequencing signals. In addition, the cryptic splice sites described previously were not present in this version of the sequence (neither in the plasmid sequence nor in the tumor-derived sequences); accordingly, no splice variant was detected in the sequencing results.

**[00192]** To investigate whether minority sequences with mutations had occurred within the tumor, two of the PCR amplicons were subcloned and sequenced. No mutation was observed in subclones of amplicon 5; in contrast, in two of the subclones of amplicon 3, there was a single point mutation (FIG. 7C) not located at critical sites of the TK enzyme (ATP and nucleotide-binding sites) (Andrei *et al.*, 2005).

**[00193]** *Transplantation of TK-NPCs produced mature neurons which were not sensitive to ganciclovir treatment:* The *in vivo* results, shown so far, were obtained with transplantation of undifferentiated pluripotent stem cells. However, the final goal of neuronal cell therapy is the transplantation of neural precursor cells, which should differentiate into mature neurons and be resistant to ganciclovir treatment. Therefore, 2-3 weeks-NPC containing neurospheres were transplanted (FIGS. 3C, 8). Under these conditions, no tumor formation was observed, even in the absence of ganciclovir treatment (FIG. 8A). In line with these observations, the transplanted cells (assessed by immunofluorescence 7 weeks after transplantation) were abundantly positive for beta 3 tubulin (FIG. 8B, upper panel), while a smaller fraction of cells was TH-positive (FIG. 8B, lower panel). Occasionally nestin-positive cells were observed. None of these markers were affected by ganciclovir treatment.

**[00194]** Markers of cellular proliferation were analyzed by staining of the transplants with antibodies against PCNA and Ki67 (FIG. 8C). Surprisingly, many of the transplanted cells were PCNA positive, while Ki67 staining of the transplants was low to absent. Ganciclovir treatment did not alter this pattern (FIG. 8C, left panels, control and right panels, ganciclovir



the HsKi67 promoter (pENTR-L4-Ki67-L1R), a pENTR plasmid containing the fusion gene TK::Sh, corresponding to the thymidine kinase (TK) gene from Herpes simplex virus type 1 (HSV1) and the Shble gene conferring zeocin resistance, and a pCLX-R4-DEST-R2 lentivector destination cassette.

5           **[00199]**   *Lentiviral vector production and titration:* Lentiviral vector stocks were generated using transient transfection of HEK 293T cells with the specific lentivector transfer plasmid, the psPAX2 plasmid encoding gag/pol and the pCAG-VSVG envelope plasmid. Lentivector titer was performed using transduction of HT-1080 cells followed by flow  
10           cytometry quantification of GFP-positive cells 5 days after infection. Cell culture: HEK 293T and HT-1080 cells were cultured in high-glucose Dulbecco's modified eagle medium (Sigma) supplemented with 10% fetal calf serum, 1% Penicillin, 1% Streptomycin, and 1% l-glutamine. Transduction of HS415 cell line: 1 up to 5 copies of the lentiviral vector were introduced. HS415 cells were cultured for 5 days before zeocin selection.

**[00200]**   *Generation of neurospheres containing DA neuroprecursors:* NPC were  
15           generated as neurospheres to contain DA progenitors as described previously (Tieng *et al.*, 2014). Briefly, neural midbrain orientation is performed during the first week followed by 2 additional weeks of maturation to obtain 1 week or 2 or 3 week-old NPC (FIGS. 1B, 3A).

**[00201]**   *Generation of NPC in two dimensional culture (2D):* For differentiation in  
20           2D, 3-week old neurospheres were dissociated with ACCUMAX® (Millipore) and replated on polyornithine- (15µg/mL; Sigma) and laminin- (2µg/cm<sup>2</sup>; R&D System) coated cover slips (diameter=0.8cm) in 24-well plates at 200,000 cells/cm<sup>2</sup> in maturation medium for 1 week before analysis by immunofluorescence staining (FIG. 1B).

**[00202]**   *Flow cytometry:* Undifferentiated ES cells were enzymatically detached as  
25           single cells from human matrix (Accutase, Invitrogen), washed with PBS before a 10 min fixation step in 4% paraformaldehyde (PFA) at room temperature. One week- or 3 week-old neurospheres were dissociated (Accutase, Invitrogen). To detect intracellular antigens, cells were permeabilized in 1x perm/wash buffer (BD bioscience) for 10 min, before 30 min  
30           incubation in the dark at room temperature with different antibodies (PE Nanog and PerCp-Cy 5.5 Oct 3/4 from Life Technology, FITC-ki67, rabbit, from Abcam) After washing, cells were immediately run or stored at 4°C for 24h maximum. For each sample run, 10,000 events were

recorded and analyzed. Flow cytometry acquisition was performed using FacsCanto I equipment with 488 and 633 lasers (BD bioscience) and data analysis by Flowjo software.

**[00203]** *Immunofluorescence staining of fixed cells:* After 1 week of culture, 2D cultures on cover slips were fixed in 4% PFA for 10min at room temperature, washed and processed for conventional immunocytochemistry. Paraffin embedded brain was sectioned and processed with cresyl violet for morphological assessment and immunohistochemistry staining. Primary antibody was incubated at 4 °C overnight in agitation in PBS+0.1 % triton for cells and 0.3% triton for tissue. Revelation is performed with a secondary antibody at room temperature for 30 min.

**[00204]** Primary antibodies were against Nestin (rabbit polyclonal anti-human, from Chemicon; 1/400),  $\beta$ 3-tubulin (mouse monoclonal from Sigma or rabbit polyclonal from Covance; 1/2,000, neuronal nuclei-specific protein (NeuN, mouse monoclonal from Chemicon; 1/1,000), glial fibrillary acidic protein (GFAP, rabbit polyclonal from Dako; 1/2,000), proliferating cell nuclear antigen (PCNA, mouse monoclonal from Dako; 1/100), tyrosine hydroxylase (TH; rabbit polyclonal from Millipore; 1/500). Detection of primary antibodies was performed using appropriate species-specific Alexa 488- or Alexa 555-labeled secondary antibodies. Controls included examination of the cell or tissue autofluorescence and omission of the first antibody. Cell nuclei were stained with DAPI. Sections and cell cultures were mounted in Fluorosave (Calbiochem) or Eukitt (Kindler GmbH) and observed with an Axioscop 2 plus microscope equipped with appropriate filters, AxioCam color camera, and Axiovision software (Leitz).

**[00205]** *Cell proliferation measurement by calcein assay:* Cells were plated onto a 96 wells pre-coated with polyornithine+ECM (1/50). Respectively 1000 cells for pluripotent stem cells, 5000 cells for early NPC and 30000 cells for late NPC. Ganciclovir (Cemevene diluted in PBS, Roche) treatment was added the day after cell plating for PSC, 3 days later for early NPC and one week later for late NPC. Calcein (2  $\mu$ M) was added for different time course of ganciclovir treatment (24H to 96H). Cell survival was measured by calcein integration after 24h of incubation in a 37°C incubator.

**[00206]** *Stereotaxic engraftment and ganciclovir treatment:* Undifferentiated pluripotent stem cells (20000 cells/  $\mu$ L) and dissociated neurospheres (100.000 cells/ $\mu$ L) were injected in the striatum of anesthetized mice using a 27-G Hamilton syringe. Injection

coordinates for lateral striatum were: bregma=0.74 mm, mediolateral=2.25 mm, dorsoventral=3.5 mm; for medial striatum: bregma=0.74 mm, mediolateral=1.4 mm, dorsoventral=2.8 mm. Mice were euthanized one month later after ganciclovir termination.

**[00207]** *Morphological and Phenotypic Analysis of Injected Surviving Cells:*

5 Anesthetized mice were fixed by intracardiac perfusion of 4% paraformaldehyde in phosphate-buffered saline. Immunohistochemical detection was performed on 10- $\mu$ m thick free-floating cryostat sections using Alexa 488-, or 555-labeled secondary antibodies or the biotin-avidin-peroxidase complex method (Vector). The following primary antibodies were used: Nestin (rabbit polyclonal anti-human, from Chemicon, 1/400),  $\beta$ 3-tubulin (mouse monoclonal from  
10 Sigma or rabbit polyclonal from Covance, 1/2000), Neuronal Nuclei-specific protein (NeuN, mouse monoclonal from Chemicon, 1/1000), Glial Fibrillary Acidic Protein (GFAP, rabbit polyclonal from Dako, 1/2000), Proliferating Cell Nuclear Antigen (PCNA, mouse monoclonal from Dako, 1/100), Tyrosin Hydroxylase (TH, rabbit polyclonal from millipore, 1/500), iba 1 (polyclonal rabbit from Wako, 1/500), HSV-TK (mouse monoclonal, Gentaur, 1/100), ki67  
15 (monoclonal rabbit, Abcam, 1/100 or mouse, Chemicon, 1/100). CD31 (Detection of primary antibodies was performed using appropriate species specific Alexa 488- or Alexa 555-labeled secondary antibodies. Controls included examination of the cell or tissue auto-fluorescence and omission of the first antibody. Cell nuclei were stained with DAPI. Sections and cells cultures were mounted in Fluorosave (Calbiochem) or Eukitt (Kindler GmbH, Germany) and observed  
20 with an Axioscop2 plus microscope equipped with appropriate filters, AxioCam color camera and Axiovision software (Leitz, Germany). Confocal imaging was achieved with an LSM 510 Meta confocal laser scanner and Bitplane SS Imaris 5.7.2 software.

**[00208]** *BrdU labelling:* BrdU (100mg/kg, Millipore) was injected intraperitoneally twice daily for 3 consecutive days. Mice were sacrificed 5 days later and perfused, through the  
25 heart, with PBS and 4% paraformaldehyde in PBS. Brain and small intestine were embedded in paraffin and 10 mm thick frontal section were processed for BrdU immunohistochemical detection using a BrdU Immunohistochemistry Kit (Chemicon, Cat No. 2760), small intestine section serving as control.

**[00209]** *Thymidine kinase sequencing:* Total RNA was extracted and purified  
30 according the manufacturers' instructions (high pure FFPE RNA micro kit, Roche) from PFA-fixed, paraffin-embedded tissue delimited to teratoma area induced by PSC transplantation and late ganciclovir treatment (IG. 7). Typically, RNA isolated from formalin-fixed tissue is



fragmented and the bulk of RNA obtained is around 200 bases in length. After DNase treatment, CDNA synthesis is performed from RNA pool extracted (Takara). Thymidine kinase gene expressed inside the teratoma was amplified by using a set of different overlapping primers along the thymidine sequence (1162bp). PCR reaction is performed with a proofreading taq polymerase (Q5 high fidelity, NEB) during 35 cycles with 30" at 95 °C, 30" at 58°C and 1 min at 72°C. Primers for fragment 1 are for forward F 5'-GAG CGGTGGTTCGACAAGTGG-3' (SEQ ID NO: 1) and reverse R 5'-CCTCAGCAGGGTTGGCATC-3' (SEQ ID NO: 2), fragment 2, F 5'-GATGCCAACCCTGCTGAGG-3' (SEQ ID NO: 3) and R 5'-GTCCAGCCTGTGCTGGGTG-3' (SEQ ID NO: 4), fragment 3, F 5'-CACCCAGCACAGGCTGGAC-3' (SEQ ID NO: 5) and R 5'-CAGGGCCACAAAAGCCAGCAC-3' (SEQ ID NO: 6), fragment 4, F 5'-GTGCTGGCTTTTGTGGCCCTG-3' (SEQ ID NO: 7) and R 5'-CCAGAGAGCTGTCCCCAGTC-3' (SEQ ID NO: 8), fragment 5, F 5'-GTCCCCTGCTGGATGCAGAG-3' (SEQ ID NO: 9) and R 5'-CTC TGC ATCCAGCAGGGGAC-3' (SEQ ID NO: 10). Fragment 1 to 5 were directly sequenced or subcloned into topo TA cloning kit (Invitrogen) before performing sequencing of the different bacterial clones (Microsynth, AG).

\* \* \*

20           **[00210]** All of the methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the methods and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit, and scope of the invention. More specifically, it will be apparent that certain agents that are both chemically and physiologically related may be substituted for the agents described herein while the same or similar results would be achieved. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope, and concept of the invention as defined by the appended claims.

30

## REFERENCES

The following references, to the extent that they provide exemplary procedural or other details supplementary to those set forth herein, are specifically incorporated herein by reference.

- Alisky and Davidson, *Hum. Gene Ther.* 77:2315-2329, 2000.
- Amit *et al.*, *Dev. Bio.*, 227:271-278, 2000.
- Andrei G, *et al.*, *Journal of virology* 79: 5863-5869, 2005.
- Balciunaite *et al.*, *Molecular and Cellular Biology* 25(18), 2005.
- Blomer *et al.*, *J. Virol.*, 71(9):6641-6649, 1997.
- Bray *et al.*, *PNAS USA* 91, 1256-1260, 1994.
- Byrne *et al.*, *Nature*, 450(7169):497-502, 2007.
- Challita, P. M. and Kohn, D. B., *Proc. Natl. Acad. Sci. USA* 91: 2567, 1994.
- Chalmers D *et al.*, *Molecular therapy : the journal of the American Society of Gene Therapy* 4: 146-148, 2001.
- Chang *et al.*, *PLOS One* 8(4):e61196, 2013.
- Chang, *et al.*, *J. Virology* 67, 743-752, 1993.
- Chen *et al.*, *Nature Methods*, 8:424-429, 2011.
- Chu *et al.*, *Gene* 13: 197, 1981.
- Couch *et al.*, *Am. Rev. Resp. Dis.*, 88:394-403, 1963.
- Daly *et al.*, *Nature* 342:816-819, 1989.
- Davidson *et al.*, *Nat. Genet.* 3:219-223, 1993.
- Davidson *et al.*, *PNAS* 97:3428-3432, 2000.
- Davis *et al.*, *Basic Methods in Molecular Biology*, Elsevier, 1986.
- Denny *et al.*, *Biomedicine Biotechnol.* 1:48-70, 2003
- Dimova *et al.*, *Oncogene* 24:2810-2826, 2005.
- Finer, *et al.*, *Blood* 83, 43-50, 1994.
- Fischer *et al.*, *Nucleic Acids Research* 2015.
- Froehler *et al.*, *Nucleic Acids Res.*, 14(13):5399-5407, 1986.
- Ganat *et al.*, *J. Clin. Invest.*, 122:2928-2939, 2012.
- Gill *et al.*, *Molecular and Cellular Biology* 33(3):498-513, 2013.
- Graham and Prevec, *Biotechnology*, 20:363-390, 1992.
- Graham *et al.*, *J. General Virology*, 36:59-74, 1977.

- Graham *et al.*, *Virology*, 52:456, 1973.
- Grant *et al.*, *Molecular Biology of the Cell* 24(23):3634-3650, 2013.
- Grunhaus and Horwitz, *Seminar in Virology*, 3:237-252, 1992.
- Huang *et al.*, *J. Virology* 65:3193-3199, 1994.
- Huang *et al.*, *Mol Cell. Biol.* 73:7476-7486, 1993.
- Imaki *et al.*, *Cancer Res.* 63(15):4607-13, 2003.
- International Publication No. PCT/JP2009/062911
- International Publication No. PCT/JP2011/069588
- International Publication No. WO 02/101057
- International Publication No. WO 2007/069666
- International Publication No. WO 95/30763
- Kang *et al.*, *Biochem Biophys Res Commun.* 420(4):822-7, 2012.
- Kotini AG, *et al.*, *Molecular therapy Nucleic acids* 5: e284, 2016.
- Kriks *et al.*, *Nature*, 480:547-551, 2011.
- Kunkle, *PNAS* 52:488, 1985.
- Levin *et al.*, *Gene* 108:167- 174, 1991.
- Llano *et al.*, *Genes Dev.* 22(17):2400-13, 2008.
- Ludwig *et al.*, *Nat. Biotechnol.*, 24(2):185-187, 2006b.
- Ludwig *et al.*, *Nat. Methods*, 3(8):637-46, 2006a.
- Macejak and Sarnow, *Nature*, 353:90-94, 1991.
- Mjelle *et al.*, *DNA Repair* 30:53-67, 2015.
- Muller *et al.*, *Nucleic Acids Res.* 40(4):1561-1578, 2012.
- Naldini *et al.*, *Science*, 272(5259):263-267, 1996.
- Pawar *et al.* *Oncogene* 23(36):6125-35, 2004.
- Pelletier and Sonenberg, *Nature*, 334(6180):320-325, 1988.
- Ren *et al.*, *Genes and Dev.* 16:245-256, 2002.
- Renan, *Radiother. Oncol.*, 19:197-218, 1990.
- Reubinoff *et al.*, *Nat. Biotechnol.*, 18:399-404, 2000.
- Robinson, *et al.*, *Gene Therapy* 2, 269-278, 1995.
- Salvatore *et al.*, *Cancer Res.* 67(21):10148-10158, 2007.
- Sambrook *et al.*, *Molecular Cloning, a laboratory manual*, Cold Spring Harbor Laboratories, New York, 1989.
- Seguin *et al.*, *Molecular and Cellular Biology* 29(2), 2009.
- Stein *et al.*, *J Virol* 73:3424-3429, 1999.

Suzuki *et al.*, *Nature Cell Biology* 18:382-392, 2016.  
Takahashi *et al.*, *Cell*, 126(4):663-76, 2007.  
Thomson and Marshall, *Curr. Top. Dev. Biol.*, 38:133-165, 1998.  
Thomson and Odorico, *Trends Biotechnol.*, 18(2):53-57, 2000.  
Tieng V, *et al.*, *Stem cells and development* 23(13):1535-1547, 2014.  
Top *et al.*, *J. Infect. Dis.*, 124:155-160, 1971.  
U.S. Patent No. 4,682,195  
U.S. Patent No. 4,683,202  
U.S. Patent No. 5,591,624  
U.S. Patent No. 5,645,897  
U.S. Patent No. 5,705,629  
U.S. Patent No. 5,843,780  
U.S. Patent No. 5,925,565  
U.S. Patent No. 5,928,906  
U.S. Patent No. 5,935,819  
U.S. Patent No. 5,980,885  
U.S. Patent No. 5,994,136  
U.S. Patent No. 6,013,516  
U.S. Patent No. 6,013,517  
U.S. Patent No. 6,103,470  
U.S. Patent No. 6,200,806  
U.S. Patent No. 6,416,998  
U.S. Patent No. 6,740,320  
U.S. Patent No. 7,029,913  
U.S. Patent No. 7,442,548  
U.S. Patent No. 7,598,364  
U.S. Patent No. 7,968,337  
U.S. Patent No. 7,989,425  
U.S. Patent No. 8,058,065  
U.S. Patent No. 8,071,369  
U.S. Patent No. 8,093,053  
U.S. Patent No. 8,129,187  
U.S. Patent No. 8,178,349  
U.S. Patent No. 8,183,038

U.S. Patent No. 8,268,620  
U.S. Patent No. 8,546,140  
U.S. Patent No. 8,691,574  
U.S. Patent No. 8,741,648  
U.S. Patent No. 8,900,871  
U.S. Patent No. 9,175,268  
U.S. Patent Publication No. 2003/0211603  
U.S. Patent Publication No. 2009/0246875  
U.S. Patent Publication No. 2010/0210014  
U.S. Patent Publication No. 2010/0323444  
U.S. Patent Publication No. 20120276636  
U.S. Patent Publication No. 2014/0315304  
Wernig *et al.*, *Proc. Natl. Acad. Sci. USA.*, 105:5856-5861, 2008.  
Westendorp *et al.*, *Nucleic Acids Research* 1-13, 2011.  
Whitfield *et al.*, *Nature Reviews Cancer* 6:99-106, 2006.  
Wu *et al.*, *J Biol Chem.* 3(43):29396-29404, 2008.  
Wu X. and Lee H. *Oncogene* 21(51): 7786-96, 2002.  
Xu *et al.*, *Nat. Biotechnol.*, 19:971-974, 2001.  
Yamamoto *et al.*, *Nucleic Acid Res.* 2016.  
Yamanaka *et al.*, *Cell*, 131(5):861-72, 2007.  
Ying *et al.*, *Cell*, 115:281-292, 2003.  
Yu *et al.*, *Science*, 318:1917-1920, 2007.  
Zambon A.C. *Cytometry A.* 77(6):564-570, 2010.  
Zapp *et al.*, *Nature* 342:714-716, 1989.  
Zhang *et al.*, *Molecular Cancer* 8(11), 2009.  
Zufferey *et al.*, *Nat. Biotechnol.*, 15(9):871-875, 1997.

**WHAT IS CLAIMED IS:**

1. An expression vector comprising a cell cycle-dependent promoter operatively linked to a suicide gene coding sequence.
2. The expression vector of claim 1, wherein the cell cycle-dependent promoter is a Ki-67, PCNA, CCNA2, CCNB2, DLGAP5, or TOP2A promoter.
3. The expression vector of claims 1-2, wherein the cell cycle-dependent promoter is a Ki-67 promoter.
4. The expression vector of claims 1-3, wherein the cell cycle-dependent promoter is a synthetic cell cycle promoter.
5. The expression vector of claims 1-4, wherein the suicide gene is a viral thymidine kinase, bacterial cytosine deaminase, nitroreductase, carboxypeptidase G2, purine nucleoside phosphorylase, or caspase 9.
6. The expression vector of claims 1-5, wherein the suicide gene is a herpes simplex virus thymidine kinase (HSV TK) gene.
7. The expression vector of claim 6, wherein the HSV TK gene is an HSV TK mutant.
8. The expression vector of claim 7, wherein the HSV TK mutant is HSV1-SR11TK, HSV1-SR26TK, or HSV1-SR39TK.
9. The expression vector of claim 7, wherein the HSV TK mutant is HSV1-SR39TK.
10. The expression vector of claims 1-9, further comprising a selectable marker.
11. The expression vector of claim 10, wherein the selectable marker is an antibiotic resistance gene or a gene encoding a fluorescent protein.
12. The expression vector of claims 1-11, further defined as a viral vector.
13. The expression vector of claim 12, wherein the viral vector is a lentiviral vector, an adenoviral vector, a retroviral vector, a vaccinia viral vector, an adeno-associated viral vector, a herpes viral vector, or a polyoma viral vector.
14. The expression vector of claim 12, wherein the viral vector is a lentiviral vector.
15. A host cell comprising an expression vector of claims 1-14.
16. The host cell of claim 15, further defined as a neural precursor cell, cardiomyocyte precursor cell, endothelial precursor cell, pancreatic precursor cell, kidney precursor




cell, oligodendrocyte precursor cell, hematopoietic precursor cell, myeloid precursor cell, mesenchymal precursor cell, retinal precursor cell, or osteoclast precursor cell.

17. The host cell of claim 15, further defined as a neural precursor cell.
18. The host cell of claims 15-17, wherein the cell is derived from a pluripotent stem cell (PSC).
19. The host cell of claim 18, wherein the PSC is an induced pluripotent stem cell (iPS cell) or embryonic stem cell (ESC).
20. The host cell of claim 17, wherein the neural precursor cell is further defined as expressing at least one of the markers selected from the group consisting of musashi, nestin, sox2, vimentin, pax6, and sox1.
21. A pharmaceutical composition comprising the host cell of claims 15-20 and optionally a pharmaceutically acceptable carrier.
22. A method of producing the host cell of claims 15-20 comprising:
  - (a) obtaining a starting population of PSCs;
  - (b) differentiating the PSCs into precursor cells; and
  - (c) isolating and culturing the precursor cells, wherein either the PSCs or the precursor cells are transfected or transduced with an expression vector in accordance with claim 1 and selected for the presence of said expression vector, such that the cultured precursor cells comprise the cell cycle-dependent promoter operatively linked to the suicide gene coding sequence.
23. The method of claim 22, wherein the precursor cells are neural precursor cells, cardiomyocyte precursor cells, endothelial precursor cells, pancreatic precursor cells, kidney precursor cells, oligodendrocyte precursor cells, hematopoietic precursor cells, myeloid precursor cells, mesenchymal precursor cells, retinal precursor cells, or osteoclast precursor cells.
24. The method of claim 22, wherein the precursor cells are a neural precursor cells.
25. The method of claims 22-24, wherein the starting population of PSCs comprises embryonic stem cells.
26. The method of claims 22-24, wherein the starting population of PSCs comprises induced pluripotent stem cells.



27. The method of claim 24, wherein differentiating cells of the population into neural precursor cells comprises contacting the starting population of PSCs with fibroblast growth factor or epidermal growth factor.
28. The method of claim 27, further comprising contacting the starting population of PSCs with N2 and B27.
29. The method of claims 22-28, wherein isolating comprises sorting the cells of the population to isolate precursor cells.
30. The method of claims 22-29, wherein cells are selected for the presence of said expression vector by a method comprising contacting the transfected or transduced cells with an antibiotic.
31. The method of claims 22-29, wherein cells are selected for the presence of said expression vector by a method comprising sorting the transfected or transduced cells.
32. A method of cell replacement therapy for replacing cells that are known to be essentially non-dividing cells, the method comprising administering an effective amount of precursor cells of claims 15-20, and administering to the subject an amount of a prodrug that is activated by the suicide gene, the prodrug being administered in an amount effective to eliminate cycling precursor cells.
33. The method of claim 32, wherein the precursor cells are neural precursor cells, cardiomyocyte precursor cells, or pancreatic precursor cells.
34. The method of claims 32-33, wherein the subject is a mammal.
35. The method of claim 34, wherein the mammal is a mouse, rat, non-human primate, or human.
36. The method of claims 32-35, wherein the genome of the host cell comprises a genome essentially identical to the genome of the subject and an expression vector of claims 1-14.
37. The method of claims 32-36, wherein the essentially non-dividing cells to be replaced comprise dopaminergic cells and the host cells comprise dopaminergic neural precursor cells, defined as expressing tyrosine hydroxylase or dopamine active transporter.
38. The method of claims 32-37, wherein the subject has Parkinson's disease.
39. The method of claims 32-38, wherein the prodrug is ganciclovir and/or acyclovir.



40. The method of claims 32-39, wherein the prodrug is administered more than once.
41. The method of claims 32-40, wherein the prodrug is administered after a sufficient period of time for the precursor cells to initiate differentiation.
42. The method of claim 41, wherein the period of time is 3-6 days.
43. The method of claim 41, wherein the period of time is 7-15 days.
44. The method of claims 32-41, wherein the prodrug is administered by injection.




FIGS. 1A-1C




**FIGS. 2A-2B**


C



D




FIGS. 2C-2D




FIGS. 3A-3C

A




PBS





B


Ganciclovir




FIGS. 4A-4B



FIGS. 5A-5B







FIGS. 7A

```

amplicons
1 plasmid atggttcttaacctggacaccagcatgcttctgacctttgaccaggctgccagatccaggggccactccaacacaggagaaatgccctaaagaccocagaaacagcagcaggaagccactgaggt
  seq atggttcttaacctggacaccagcatgcttctgacctttgaccaggctgccagatccaggggccactccaacacaggagaaatgccctaaagaccocagaaacagcagcaggaagccactgaggt
plasmid gaggcctgagcagaagatgccaaacctgctgagg
  seq gaggcctgagcagaagatgccaaacctgctgagg
2 plasmid gtgtacattgatggacctcatggcatgggcaagaccaccactcaactgctggtggcactgggtccaggatgacattgtgtatgtgcctgagccaatgacctactggagagtcttagggg
  seq gtgtacattgatggacctcatggcatgggcaagaccaccactcaactgctggtggcactgggtccaggatgacattgtgtatgtgcctgagccaatgacctactggagagtcttaggga
plasmid cctctgagaceattgccaaactctccaccagcacaggctggacc
  seq cctctgagaceattgccaaactctccaccagcacaggctggacc
3 plasmid agggagaatactctgctggagatgctgtctgtggtgatgacctctgccagatcacaatgggaatgacctatgctgtgactgatgctgttctggctcctcacattggaggaggctggctcttctcat
  seq agggagaatactctgctggagatgctgtctgtggtgatgacctctgccagatcacaatgggaatgacctatgctgtgactgatgctgttctggctcctcacattggaggaggctggctcttctcat
plasmid gcccctccacctgccctgacctgatctttgacagacacccccattgcagccctgctgtctaccagcagcaaggtacctcatgggctccatgacccccacaggtct
  seq gcccctccacctgccctgacctgatctttgacagacacccccattgcagccctgctgtctaccagcagcaaggtacctcatgggctccatgacccccacaggtct
4 plasmid gtgcggcttttgtggccctgatccctceaacctccctggaacaaeatgtttctgggagcactgctgaaacagacacacattgcacaggctggcaagaggeagacctggagagagactg
  seq gtgcggcttttgtggccctgatccctceaacctccctggaacaaeatgtttctgggagcactgctgaaacagacacacattgcacaggctggcaagaggeagacctggagagagactg
plasmid gaccggccatgctggctgcaatcagaagggtgtatggactgctgcaaacactgtgatacctccagtgctggaggctcttggagagaggactggggacagctctctg
  seq gaccggccatgctggctgcaatcagaagggtgtatggactgctgcaaacactgtgatacctccagtgctggaggctcttggagagaggactggggacagctctctg
5 plasmid atgctctgctgcaactaacctctggcatggtgcagaccctatggaccaccctggcagcatccccaccactctgtgacctagccagaaaccttggccaggagatgggaatctctggagccaatgg
  seq atgctctgctgcaactaacctctggcatggtgcagaccctatggaccaccctggcagcatccccaccactctgtgacctagccagaaaccttggccaggagatgggaatctctggagccaatgg
plasmid agtcatggccaagttagccagtgtctg
  seq agtcatggccaagttagccagtgtctg

```

FIG. 7B





FIG. 7C



FIGS. 8A-8D

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 17/40303

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(8) - A61K 48/00; C12N 15/00; C12N 5/07; C12N 5/071; C07H 21/04 (2017.01)

CPC - A61K 48/00; C12N 15/86; C12N 2740/15011; C12N 15/8645; C12N 15/867; C12N 15/861; C12N 15/63; C12N 5/10; C12N 5/0602; A61K 35/12; C07K 14/005

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

See Search History Document

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

See Search History Document

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

See Search History Document

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X — Y	US 2014/0057969 A1 (THE REGENTS OF THE UNIVERSITY OF CALIFORNIA) 27 February 2014 (27.02.2014), Abstract, para [0007], [0020], [0022], [0153], [0287], and [0288]	1 ----- 2-3
Y	Zambon, Use of the Ki67 Promoter to Label Cell Cycle Entry in Living Cells. Cytometry A. 2010, Vol. 77(6), p. 564-70. Abstract; pg 565, col 1, para 1, last para, col 2, top para, and Fig 1; and pg 569, col 1, middle para	2-3
Y (an alternative)	US 2012/0117668 A1 (FLEISCHMANN et al.) 10 May 2012 (10.05.2012), Abstract, para [0036], [0046], [0049], [0137], [0162], and [0186]	2-3
A	HOFFMANN et al., Efficient generation of double heterologous promoter controlled oncolytic adenovirus vectors by a single homologous recombination step in Escherichia coli. BMC Biotechnol. 2006, Vol. 6:36. PDF File: pg 1-12. Entire documentation, especially Abstract; pg 2, col 2, last para; pg 3, col 1, top para, and para 3; pg 5, Fig 2; and pg 7, col 2, para 3	1-3
P,X	TIENG et al., Elimination of proliferating cells from CNS grafts using a Ki67 promoter-driven thymidine kinase. Mol Ther Methods Clin Dev. 2016 Nov, Vol. 6:16069. PDF File: pg 1-12. Entire documentation, especially Abstract; pg 2, col 1, para 1-3; pg 3, Fig 1; and pg 5, col 1, and Fig 3	1-3

 Further documents are listed in the continuation of Box C. See patent family annex.

## \* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&amp;" document member of the same patent family

Date of the actual completion of the international search

14 August 2017

Date of mailing of the international search report

27 OCT 2017

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents  
P.O. Box 1450, Alexandria, Virginia 22313-1450  
Facsimile No. 571-273-8300

Authorized officer:

Lee W. Young

PCT Helpdesk: 571-272-4300  
PCT OSP: 571-272-7774

INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 17/40303

**Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)**

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2.  Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
  
3.  Claims Nos.: 4-44  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:  
This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

Groups I+, Claims 1-3, directed to an expression vector comprising a cell cycle-dependent promoter operatively linked to a suicide gene coding sequence. The cell cycle-dependent promoter will be searched to the extent that the cell cycle-dependent promoter encompasses the first named Ki-67 promoter. It is believed that claims 1, 2(in part), 3 encompass this first named invention, and thus these claims will be searched without fee to the extent that they encompass wherein the cell cycle-dependent promoter encompasses Ki-67 promoter. Additional cell cycle-dependent promoters will be searched upon the payment of additional fees. Applicants must specify the claims that encompass any additionally elected cell cycle-dependent promoter(s).

\*\*\*\*\*Continued in the extra sheet\*\*\*\*\*

1.  As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
  
2.  As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
  
3.  As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
  
4.  No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:  
1, 2(in part), 3, limited to Ki-67 promoter

- Remark on Protest**
- The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
  - The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
  - No protest accompanied the payment of additional search fees.

Continuation of:  
Box No III (unity of invention is lacking)

(Continuation of Groups I+) Applicants must further indicate, if applicable, the claims which encompass the first named invention, if different than what was indicated above for this group. Failure to clearly identify how any paid additional invention fees are to be applied to the "+" group(s) will result in only the first claimed invention to be searched. An exemplary election would be wherein the cell cycle-dependent promoter encompasses PCNA (proliferating cell nuclear antigen) promoter (Specification: para [00204] - 'proliferating cell nuclear antigen (PCNA)' [claims (1), 2(in part)])

The inventions listed as Groups I+ do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

**Special Technical Feature**

Among Groups I+, each promoter is structurally and regulatorily different from all others.

**Common Technical Features.**

The inventions of Groups I+ share the technical feature of an expression vector comprising a cell cycle-dependent promoter operatively linked to a suicide gene coding sequence (claim 1).

However, this shared technical feature does not represent a contribution over prior art as being anticipated by US 2014/0057969 A1 to THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (hereinafter 'UNIV\_CALIFORNIA') as follows:

UNIV\_CALIFORNIA discloses an expression vector comprising a cell cycle-dependent promoter (Abstract - 'vectors exhibit... anti-tumor'; para [0007] - 'vectors provided herein can contain at least one promoter... to control expression of a first and/or second open reading frame'; para [0020] - 'tumor-specific promoter is a cell-cycle dependent promoter')  
--operatively linked to a suicide gene coding sequence (para [0007] - 'non-viral nucleic acid vector constructs ...vectors ...contain at least one promoter that is operatively linked to control expression of a first and/or second open reading frame'; para [0022] - 'vector can include an open reading frame coding for a bystander protein that is a prodrug modifying protein...HSV-TK'; para [0153] - 'prodrug modifying gene... refer to a suicide gene that encodes a polypeptide that converts a prodrug to a toxic compound. ... suicide prodrug modifying gene is herpes simplex 1 thymidine kinase gene (HSV-TK)'; para [0288] - 'nucleic acid constructs that contain a synthetic TK transcription unit containing a cell cycle dependent promoter, an HSV1-TK gene').

Without a shared special technical feature, the inventions lack unity with one another.

Groups I+ therefore lack unity under PCT Rule 13 because they do not share a same or corresponding special technical feature.

Continuation of item 4: Claims 4-44 are not drafted in accordance with the second and third sentences of Rule 6.4 (a). These claims are improper multiple dependent claims.

**Note:**

1) There is no full name for each of the abbreviations CCNA2, CCNB2, DLGAP5, and TOP2A disclosed in the Specification.